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ABSTRACT 
 
Malaysian Chinese are highly susceptible to Epstein-Barr virus (EBV)-
associated nasopharyngeal carcinoma (NPC). Because NPC is often diagnosed at a late 
stage, accurate EBV serologic tests might be useful to detect NPC in patients with 
subtle symptoms. And because EBV serological data for Malaysian Chinese are 
currently lacking, we sought to develop indirect enzyme-linked immunosorbent assays 
(ELISAs) for a case-control study of NPC in Malaysian Chinese. 
Of the 165 cases and 658 controls recruited, 89.7% (148/165) prevalent NPC 
cases were Chinese, in which 14.2% (21/148) Chinese patients were familial NPC cases. 
The prevalence of family history of NPC among the Chinese controls was 0.6% (2/334), 
whereas none of the controls of other ethnicity (n = 324) had family history of NPC. 
Based on individual matching in age and gender, 120 case-control pairs of Chinese 
descent were selected for the subsequent ELISA study. 
Using recombinant DNA technology, three EBV proteins: early antigen-diffuse 
(EA-D), Z-encoded broadly reactive activator (ZEBRA) and viral capsid antigen (VCA) 
p18, were expressed in and purified from Escherichia coli. The EBV proteins were used 
as antigens for indirect ELISAs.  
The antibody levels against the EBV proteins were elevated in NPC cases. 
Among the serologic tests, the diagnostic accuracy of ZEBRA/IgG (81.7% sensitivity, 
61.7% specificity) was the highest, followed by VCA p18/IgG (95.8% sensitivity, 35.0% 
specificity) and EA-D/IgG (74.2% sensitivity, 48.3% specificity). To serve as useful 
clinical indicators for NPC, further efforts are needed to improve the accuracies of EBV 
serologic tests. 
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ABSTRAK 
 
Masyarakat Cina di Malaysia adalah golongan yang berisiko tinggi mengidap 
karsinoma nasofarinks (nasopharyngeal carcinoma, NPC) yang berkaitan dengan virus 
Epstein-Barr (EBV). Disebabkan NPC sering didiagnos pada peringkat lewat, ujian-
ujian serologi EBV yang tepat berpotensi untuk mengesani NPC bagi pesakit yang tiada 
gejala jelas. Dan disebabkan data serologi EBV untuk masyarakat Cina masih terhad, 
kami ingin membina asai-asai imunosorben bergabung enzim (enzyme-linked 
immunosorbent assays, ELISAs) tidak langsung untuk kajian kes-kawalan bagi 
masyarakat Cina di Malaysia. 
Antara 165 kes dan 658 kawalan yang telah rekrut, 89.7% (148/165) kes lazim 
NPC terdiri daripada kaum Cina, di mana 14.2% (21/148) pesakit Cina adalah kes NPC 
keluarga. Kadar kelaziman sejarah keluarga NPC di kalangan kawalan Cina adalah 0.6% 
(2/334), manakala kawalan-kawalan kaum lain (n = 324) tidak mempunyai sejarah 
keluarga NPC. Dengan pemadanan individu dari segi umur dan jantina, 120 pasangan 
kes-kawalan yang berketurunan Cina dipilihkan untuk kajian ELISA yang seterusnya. 
Dengan teknologi DNA rekombinan, protein-protein EBV, iaitu EA-D (early 
antigen-diffuse), ZEBRA (Z-encoded broadly reactive activator) and VCA (viral capsid 
antigen) p18, dieskpreskan dan ditulenkan dari Escherichia coli. Protein-protein EBV 
tersebut digunakan sebagai antigen-antigen dalam asai-asai ELISA tidak langsung. 
Aras-aras antibodi terhadap protein-protein EBV bagi kes-kes NPC didapati 
meningkat. Antara ujian-ujian serologi, ketepatan diagnostik bagi ZEBRA/IgG (81.7% 
sensitiviti, 61.7% spesifisiti) adalah terbaik, diikuti oleh VCA p18/IgG (95.8% 
sensitiviti, 35.0% spesifisiti) dan EA-D/IgG (74.2% sensitiviti , 48.3% spesifisiti). 
Untuk penggunaan sebagai penunjuk klinikal NPC, usaha yang selanjutnya adalah 
diperlukan untuk meningkatkan ketepatan bagi ujian-ujian serologi EBV. 
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CHAPTER 1. INTRODUCTION 
 
Global cancer statistics revealed about 84,400 incident cases of nasopharyngeal 
carcinoma (NPC), causing 51,600 deaths and contributing 0.7% of global cancer burden 
in 2008 (Jemal et al., 2011). NPC is one of the rare cancers in the world, however, NPC 
was the fourth most common cancer among Malaysians and the third most common 
cancer among males in Malaysia in 2007 (Zainal Ariffin Omar & Nor Saleha Ibrahim 
Tamin, 2011). Among various ethnic groups in Malaysia, Chinese and Bidayuh 
populations are highly susceptible to NPC (Devi et al., 2004; Pua et al., 2008; Zainal 
Ariffin Omar & Nor Saleha Ibrahim Tamin, 2011). 
Patients having symptoms suggesting NPC may be diagnosed early by 
otolaryngologist. However, the majority of NPC cases may not have clear symptoms 
until an advanced stage (stages III and IV) (Wei & Sham, 2005). For new NPC cases in 
Malaysia, neck lumps were the most common symptom (42%), followed by non-
specific symptoms (nasal obstruction (30%), aural problems (11%), and headache (5%)), 
cranial nerve (6%) and other symptoms (6%) (Pua et al., 2008). Although imaging 
examinations, i.e., computed tomography, magnetic resonance imaging (MRI) and 
positron emission tomography, can provide invaluable information about the primary 
and recurrent tumors, patients in developing countries, such as Malaysia, often have 
limited or delayed access to those imaging systems. In addition, non-invasive, reliable 
laboratory tests for detection of NPC are still lacking. 
Because Epstein-Barr virus (EBV) is one of the causative agents of NPC 
(International Agency for Research on Cancer (IARC) Working Group, 1997; Young & 
Rickinson, 2004), and anti-EBV antibody levels were found to be elevated in NPC 
patients (Henle et al., 1970; Ho et al., 1976; Gan et al., 1996), EBV serologic screening 
programs are routinely conducted in endemic regions such as southern China, Hong 
Kong and Taiwan (Chien et al., 2001; Ji et al., 2007; Ng et al., 2009b; Yu et al., 2011). 
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Physical examinations on heck and neck are performed in parallel, providing a better 
quality of health care to suspected cases and individuals with family history of NPC. 
However, such efforts are still lacking in Malaysia. 
We aim to develop and evaluate the diagnostic performances of in-house 
ELISAs for a case-control study of NPC in Malaysian Chinese, using recombinant EBV 
protein produced by Escherichia coli. In this study, the relationships between anti-EBV 
IgG levels and NPC in our case-control samples were explored. We did not study anti-
EBV IgA levels because they are examined by another student in the same laboratory. 
Our study samples were plasma that were obtained from prevalent NPC patients 
during their follow-up appointments at otorhinolaryngology clinic of University Malaya 
Medical Center (UMMC), and normal subjects during blood donation campaigns 
conducted by UMMC. Because samples from incident/recurrent NPC patients were not 
available to us, we wanted to determine if our in-house assays (developed in the present 
work) can classify the remission cases and controls satisfactory, which, in turn, (i) may 
provide us data to conduct an active follow-up for the patients who have strong positive 
EBV serologic tests before the recurrence of NPC, and (ii) may provide us a 
justification to acquire samples from incident and recurrent NPC patients through a 
multicenter collaboration in the near future. The attempt to classify remission cases 
from controls is a challenging task because the anti-EBV antibody levels in remission 
patients may be unchanged, elevated or decreased, depending on their treatment 
outcomes and clinical status of NPC (Lynn et al., 1985; De-Vathaire et al., 1988; Neel 
& Taylor, 1990; Yip et al., 1994; Baizig et al., 2012). In this context, we anticipate the 
diagnostic performances of in-house EBV serologic tests on the classification of 
incident/recurrent NPC cases and controls in the near future would be more promising 
than the present results. 
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The objectives of the present study are (i) to express and purify recombinant 
EBV proteins, i.e., early antigen-diffuse (EA-D), Z-encoded broadly reactive activator 
(ZEBRA) and viral capsid antigen (VCA) p18, from Escherichia coli, (ii) to develop 
IgG-based indirect ELISAs using the recombinant EBV proteins for a case-control 
study of NPC in Malaysian Chinese, and (iii) to obtain the diagnostic performances for 
the in-house ELISAs. 
 
 
 
 
 
CHAPTER 2. LITERATURE REVIEW 
4 
 
CHAPTER 2. LITERATURE REVIEW 
 
2.1. NPC 
NPC is one of the head and neck cancers, arises in the epithelial lining 
(squamous, respiratory and transitional epithelium) of the nasopharynx (Tang et al., 
2012). Besides NPC, wide range of tumors may arise in the nasopharynx. However, 
NPC is unique because its incidence rate is only high in certain ethnic groups and 
geographical regions (Curado et al., 2007; Jemal et al., 2011). 
 
2.1.1. Histological subtypes 
World Health Organization (WHO) classified NPC in 1978, and revised it in 
1991 and 2003 (Barnes et al., 2005). The classification of NPC is based on the 
differentiation status of malignant squamous cells observed under light microscope 
(Pathmanathan et al., 1995). 
In 1978 WHO classification, NPC was categorized into WHO type 1, 2 and 3, 
which correspond to squamous cell carcinoma, non-keratinizing carcinoma and 
undifferentiated carcinoma, respectively (Shanmugaratnam & Sobin, 1978). 
However, conflicting points of view led to a revision of NPC classification, in 
which one argued that WHO type 2 and 3 have overlapping histologic patterns, and 
resemblance in epidemiologic and biologic features; the other considered that the 
existing classification is well standardized in literature, and could favor further 
characterization (Shanmugaratnam & Sobin, 1993). Therefore, 1991 WHO 
classification abolished the numerical designation by emphasizing type 1 NPC as 
keratinizing squamous cell carcinoma, and combining type 2 and 3 NPC as non-
keratinizing carcinoma, which subdivides into differentiated and undifferentiated 
patterns (Shanmugaratnam, 1991).  
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In 2003, basaloid squamous cell carcinoma was added to 1991 WHO 
classification (Barnes et al., 2005). Nevertheless, 1978 WHO classification remains 
widely used by researchers. To synchronize with literature, here we retain the 
nomenclature from 1978 WHO classification. 
 
 2.1.2. Geographical distribution and ethnicity 
 In most populations, NPC is a rare cancer that account for below one of age-
standardized rate (ASR) per 100,000 world population (Curado et al., 2007). However, 
NPC is one of the leading cancers in endemic regions such as Greenland, southern 
China, Hong Kong, Taiwan and Southeast Asia (Jemal et al., 2011). 
In these endemic regions, certain ethnic and/or sub-ethnic groups are more 
susceptible to NPC, (i) Inuit in Greenland (Friborg et al., 2005), (ii) Cantonese descent 
of Chinese in southern China and Hong Kong (Yu & Yuan, 2002; Jia, 2008), (iii) 
Chinese in Taiwan, Malaysia and Singapore (Chen et al., 1988; Zainal Ariffin Omar & 
Nor Saleha Ibrahim Tamin, 2011; Lee et al., 2012), and (iii) Bidayuh in Sarawak (Devi 
et al., 2004).  
It should be noted that most Chinese descent in Malaysia and Singapore share a 
common ancestry, having their roots in Guangdong (Canton) and Fujian provinces of 
southern China. Because NPC is common among Cantonese, it is well known as 
‘Kwangtong tumor’ or ‘Cantonese cancer’ (Ho, 1978; Jia, 2008). However, an 
epidemiological study (1996-1998) in Sarawak (a province of Malaysia located in the 
island of Borneo) revealed that the NPC incidence rate in a native population, Bidayuh 
was exceptionally high (ASR for male, 31.5/100,000, and for female, 11.8/100,000), 
exceeding the record of Hong Kong population (ASR for male, 21.4/100,000, and for 
female, 8.3/100,000) (Devi et al., 2004). Therefore, the burden of NPC in Malaysia 
deserves extensive investigations. 
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2.1.3. Age-incidence curves 
 NPC incidence rate increases with age. Interestingly, low-risk (in certain areas in 
Indian, Japan, North America, northwest Europe and Australia) and high-risk (in certain 
areas or populations in Philippines, Singapore and Thailand) populations exhibit 
different patterns of age-incidence curves (1983–1997) (Figure 2.1) (Bray et al., 2008). 
Regardless of geographical area and gender, the age-incidence curves of NPC for low-
risk populations demonstrated a first peak at 15–24 years and a second peak at 65–79 
years. By contrast, no bimodality in the age-incidence curves of NPC for high-risk 
populations, which singly peaked at 45-60 years. 
Notably, most NPC cases in low-risk populations were WHO type 1 but those in 
high-risk populations were WHO type 3. In low-risk populations, type 2 and 3 NPC 
cases may correspond to the first peak of incidence, while type 1 NPC cases may 
correspond to the second peak of incidence (Burt et al., 1992; Vaughan et al., 1996; 
Ayan et al., 2003; Bray et al., 2008;). 
The type 1 NPC in low-risk population is plausibly associated with 
environmental (occupational exposures) and lifestyle (alcohol and cigarette) factors, 
which resulted in late sporadic NPC; the type 2 and 3 NPC in low-risk population are 
plausibly associated with genetic and environmental (EBV infection) factors, which 
resulted in familial and early sporadic NPC (Vaughan et al., 1996; IARC Working 
Group, 1997; Vaughan et al., 2000; Bray et al., 2008). 
By contrast, the type 3 NPC in high-risk population is plausibly associated with 
genetic, environmental (EBV infection and occupational exposures) and lifestyle (salt-
preserved foods and alcohol) factors (Bray et al., 2008; Bei et al., 2012; Jia & Qin, 2012; 
Tsao et al., 2012). The etiology of NPC, particularly for Malaysian Chinese, will be 
further discussed in Section 2.1.5. 
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Figure 2.1. Aggregated age-specific incidence rates of NPC by gender in (A) low-risk 
and (B) high-risk populations. The rates were calculated by weighting the counts and 
person-years by the square root of the total population in period 1983–1997. The 
registry data (annual detailed dataset for Cancer Incidence in Five Continents, volume 
I–VIII) for low-risk populations covered certain areas in Indian, Japan, North America, 
northwest Europe and Australia, while for high-risk populations covered certain areas or 
populations in Philippines, Singapore and Thailand. Black vertical lines highlight the 
age boundaries of interest (adapted from Bray et al., 2008). 
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In Peninsular Malaysia, three major ethnic groups, Malay, Chinese and Indian, 
were taken into account in Malaysian Cancer Statistics 2006 (Zainal Ariffin Omar et al., 
2006). It was reported that the NPC incidence rate in Chinese (ASR for male, 
14/100,000, and for female, 3.8/100,000) was at least threefold higher than other ethnic 
groups (Malay: ASR for male, 4/100,000, and for female, 1.3/100,000; Indian: ASR for 
male, 1/100,000, and for female, 0.2/100,000). Regardless of ethnicity, the NPC 
incidence rate for male (ASR of 8.5/100,000) was also threefold higher than female 
(ASR of 2.6/100,000).  
In 2006, the age-incidence curves of NPC for Malaysian Chinese peaked at 50–
59 year (Figure 2.2). By contrast, the male populations of Malay and Indian over 70 
years of age conferred the highest NPC incidence rates. 
 
 
Figure 2.2. Age-specific incidence rate of NPC by ethnic and gender in Peninsular 
Malaysia 2006. Data source: Malaysian Cancer Statistics 2006 (Zainal Ariffin Omar et 
al., 2006). 
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Besides, we observed a notable similarity between the age-incidence curves of 
NPC in 2006 for the male populations of Malaysian Chinese and Hong Kong 
(Malaysian Cancer Statistics 2006 (Zainal Ariffin Omar et al., 2006); Hong Kong 
Cancer Statistics 2006) (Figure 2.3). Among the three regions, the NPC incidence rates 
by age groups were relatively lower in Taiwan (Taiwan Cancer Registry, 2006). 
It should be noted that the cancer registries in Hong Kong and Taiwan did not 
publish NPC incidences by ethnicity. Nevertheless, 95% Hong Kong population was 
Chinese, according to 2006 Population By-census Office, Census and Statistics 
Department, Hong Kong; 98% Taiwan population in 2006 was Chinese, according to 
Monthly Bulletin of Interior Statistics, Taiwan. Therefore, Figure 2.3 roughly 
superimposes the age-incidence curves for Chinese in the three endemic regions in the 
same year. 
 
 
 
Figure 2.3. Age-specific incidence rate of NPC by gender, among the populations of 
Hong Kong, Taiwan and Peninsular Malaysia (Chinese) in 2006. Data source: Hong 
Kong Cancer Statistics 2006, Malaysian Cancer Statistics 2006 (Zainal Ariffin Omar et 
al., 2006) and Taiwan Cancer Registry, 2006. 
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2.1.4. Secular trends 
 The NPC incidence rates in Hong Kong, Taiwan and Singapore decreased over 
the past two decades (Lee et al., 2003; Hsu et al., 2006; Luo et al., 2007). Based on the 
four annual reports of cancer statistics available to date (The First Report of the 
National Cancer registry 2002 (Lim et al., 2003), Second Report of the National Cancer 
registry 2003 (Lim & Halimah Yahaya, 2004) and Malaysian Cancer Statistics 2006 
(Zainal Ariffin Omar et al., 2006), National Cancer Registry Report 2007 (Zainal 
Ariffin Omar & Nor Saleha Ibrahim Tamin, 2011)), the NPC incidence rate in 
Peninsular Malaysia also decreased from 2002 to 2003, 2003 to 2006, and 2006 to 2007. 
By contrast, the NPC incidence rate in southern China remained stable over time (Jia et 
al., 2006). 
In age-period-cohort models (1973–1997), NPC incidence rates were 
significantly decreased for cohorts of Chinese who were born after 1940 and 1958 in 
Hong Kong and Singapore, respectively (Luo et al., 2007). The observations are in 
agreement with the changing of lifestyles after the economic rose in Hong Kong (end of 
Pacific war in 1945) and Singapore (independence in 1965) (Yu & Yuan, 2002). By 
contrast, economic in China reformed in 1978 but only began to grow rapidly in 1990s, 
the impact on NPC incidence rate in 1973–1997 was not obvious (Jia et al., 2006). 
Because no published data across the timeline, we cannot rule out the effect of birth 
cohort on NPC incidence rate in Malaysia. 
 
2.1.5. Etiology 
 Based on the epidemiological observations (geographical distribution, ethnicity, 
age-incidence curves and secular trends), genetic, environmental and lifestyle factors 
should be closely associated with NPC. The complex interactions between these factors 
may lead to NPC. 
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The environmental risk factors for NPC include occupational exposures and 
EBV infection (Jia & Qin, 2012; Tsao et al., 2012). Because nasopharynx is responsible 
in filtering small particles at upper airway (Jaeger & Blank, 2011), certain harmful 
inhalants are linked with NPC. A study on the etiology of NPC in Malaysian Chinese 
found that wood dust and industrial heat were positively associated with NPC; in 
contrast with other studies, no association of formaldehyde exposure with NPC was 
found (Armstrong et al., 2000). 
Lifestyles, mainly dietary risk factors for Malaysian Chinese NPC cases were 
also explored, in which the consumptions of salt-preserved foods (fish, leafy vegetables, 
egg and root), fresh organs (pork or beef) and alcohol (beer and liquor) showed strong 
positive associations with NPC, whereas the consumptions of fresh fruits and vegetables 
showed strong negative associations with NPC (Armstrong et al., 1998). In particular, 
childhood consumption of salted fish conferred significant and consistent association 
with NPC among Chinese populations in different geographical regions (Armstrong et 
al., 1983; Yu et al., 1986; Yu et al., 1988; Ning et al., 1990; Yang et al., 2005; Jia et al., 
2010). It was postulated that nitrosamines and nitrosamine precursors from salt-
preserved foods contribute to NPC carcinogenesis.  
 To understand the genetic susceptibility to NPC, recently, three genome-wide 
association studies (high-throughput genotyping of single nucleotide polymorphisms) 
were performed, recruiting the NPC cases and controls of Chinese from Malaysia, 
Singapore, Taiwan and southern China (Ng et al., 2009a; Tse et al., 2009; Bei et al., 
2010). Their most consistent results suggested that human leukocyte antigen (HLA) 
genes, in particular HLA-A gene, are strongly associated with NPC. In fact, the 
associations of HLA genes (HLA-A, HLA-B, HLA-Cw, HLA-DP, HLA-DQ, and HLA-
DR genes) with NPC have been suggested by previous candidate gene studies that can 
be dated back to 1974, when HLA-A2 was found to be positively associated with NPC 
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in Singapore Chinese (Simons et al., 1974; Bei et al., 2010; Hassen et al., 2010). It is 
plausible that the antigen-presentation genes involve in pathogenesis of EBV in NPC, 
because the expression levels of HLA genes (HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, 
and HLA-G genes) were inversely correlated with EBV genes (genes for EBV nuclear 
antigens (EBNA-1, EBNA-2, EBNA-3A, and EBNA-3B), and latent membrane proteins 
(LMP-1, and LMP-2A)), especially EBNA-1 in NPC tissues (Sengupta et al., 2006). 
However, it is currently unclear for the relationships between the polymorphisms of 
HLA genes, their expression levels, and the role of EBV in tumorigenesis of NPC. 
  
2.2. EBV 
The modes of viral entry into normal human primary epithelial cells were 
demonstrated by both direct infection and B-cell mediated transfer infection of EBV 
(Feederle et al., 2007). In particular at nasopharynx, direct infection of EBV is more 
plausible due to the lack of cell-to-cell contact. 
Despite EBV infects and persists lifelong in 90% of world population, EBV is 
widely agreed as a causative agent of NPC (IARC Working Group, 1997; Young & 
Rickinson, 2004). EBV seroconversion was observed in Malaysian children, in which 
the primary infection occurred at four to five month of ages, and all have seroconverted 
by eight years of age (Yadav et al., 1987). Childhood EBV infection was also observed 
in Hong Kong and other developing countries (Kangro et al., 1994). It may be due to 
overcrowding and/or poor hygiene because EBV transmits easily via saliva (Hudnall & 
Stanberry, 2006). EBV infection in early life is subclinical, but it may involve in 
tumorigenesis of NPC in later life (IARC Working Group, 1997), possibly by re-
infection and/or recurrent reactivations of EBV (Chien et al., 2001; Fang et al., 2009). 
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2.2.1. Serological methods 
The association of EBV with NPC was shown in early findings, which employed 
immunofluorescence assay (IFA) for the detection of circulating antibodies against EBV 
proteins in NPC sera (Henle et al., 1970; Ho et al., 1976). However, the 
immunodetection method is (i) dependent on the batch-to-batch reproducibility of EBV 
antigen-expressing cells (chemically induced P3HR-1 and Raji cells to produce VCA 
and EA complexes, respectively), (ii) time-consuming, (iii) difficult to automate, and (iv) 
lack of consensus on fluorescence counting among research groups. 
Because studies have shown an acceptable concordance between IFA and 
ELISA results (Dölken et al., 1984; Luka et al., 1984), ELISA was widely adopted in 
EBV serology in the past two decades (Gan et al., 1996). Recently, studies using 
Luminex multi-analyte profiling were conducted in southern China, using recombinant 
proteins (VCA-gp125, EA-D, and EBNA-1) and synthetic peptides (VCA-p18, EBNA-
1, gp78, gp350/220 and BLRF1) of EBV (Gu et al., 2008a; Gu et al., 2008b; Gu et al., 
2009a; Gu et al., 2009b). But this technology is not yet generalized in hospitals and 
diagnostic laboratories, limiting it from routine serologic test. Moreover, the overall 
diagnostic performances (EA-D/IgG, EA-D/IgA, EBNA-1/IgA, and VCA/IgA) of 
commercial ELISA kits were better than their in-house assays (Gu et al., 2008b). 
ELISA is popular because (i) coating and preparation of solid phase (commonly 
a 96-well polystyrene microplate) is versatile and reproducible, (ii) its routine run 
required less technical expertise than IFA (For example, ELISA reader records optical 
signals for samples instead of fluorescence microscopic counting in IFA), (iv) it can be 
fully automated for high-throughput screening of samples, and therefore (v) cost-
effective and (vi) time-saving. 
We adopted indirect ELISA in the present work. The key steps of indirect 
ELISA (Figure 2.4) include (i) coating of the targeted antigen on a solid phase, (ii) 
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blocking of the remaining active surface of the solid phase after antigen immobilization, 
(iii) antigen-antibody binding (primary antibody from plasma), (iv) probing of primary 
antibody by enzyme-conjugated secondary antibody, (v) wash steps in between step i to 
iv, (vi) development of optical signal by enzyme-substrate reaction, and (vii) stopping 
of the enzyme-substrate reaction (Crowther, 2009). 
 
 
Figure 2.4. Key steps of indirect ELISA: (i) coating of targeted antigen on a solid phase, 
(ii) blocking of the remaining binding surface with blocking agent, (iii) binding of 
primary antibody in plasma to the immobilized antigen, (iv) probing of primary 
antibody by enzyme (E)-conjugated secondary antibody, (v) wash steps in between step 
i to iv, (vi) development of optical signal by enzyme-substrate reaction, and (vii) 
stopping of the enzyme-substrate reaction with stop reagent (S). 
 
2.2.2 Analytical sample 
 Serum and plasma are extracellular components of blood for medical laboratory 
studies. There are three types of plasma, i.e., citrated plasma, EDTA plasma and 
heparinized plasma. These analytical samples should be used selectively because of the 
disparities in matrix components (Working Group on Preanalytical Variables, 1998). 
For EBV serology, the working group suggested serum as the analytical sample 
of choice. Despite of the recommendation, previous studies employed sera and/or 
plasma for EBV serology, in which one of the studies showed that the ELISA results 
(IgG- and IgA-based assays, using synthetic peptides from (i) EBNA-1 of EBV, (ii) 
phosphoprotein pp150 of cytomegalovirus, and (iii) early and late proteins of human 
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papillomaviruses) for sera and EDTA plasma were identical (n = 28) (Dillner et al., 
1994). In the present study, we used EDTA plasma because only EDTA plasma were 
available. 
 
2.2.3 Serologic markers 
Because of re-infection and/or reactivation of EBV (Chien et al., 2001; Fang et 
al., 2009), previous ELISA studies (in both endemic and non-endemic regions) have 
found the elevated levels of anti-EBV antibodies in NPC cases, in particular type 2 and 
3 NPC, and further evaluated the diagnostic and prognostic values of anti-EBV 
antibodies as surrogate biomarkers for NPC (Cheng et al., 1993; Mathew et al., 1994; 
Gan et al., 1996; Chien et al., 2001; Dardari et al., 2001, 2008; Cheng, 2002; Chan et al., 
2003; Karray et al., 2005; Fachiroh et al., 2006; Hu et al., 2007; Ji et al., 2007; Paramita 
et al., 2007; Tedeschi et al., 2007; Ng et al., 2009b; Abdulamir et al., 2010; Fachiroh et 
al., 2010; Paramita et al., 2011; Yu et al., 2011). To achieve early diagnosis of NPC, 
EBV serologic screening and physical examinations have became routine clinical 
checkup for suspected cases and individuals with family history of NPC in endemic 
regions such as southern China, Hong Kong, and Taiwan (Chien et al., 2001; Ji et al., 
2007; Ng et al., 2009b; Yu et al., 2011). But such efforts are still lacking in Malaysia. 
Some EBV proteins are highly immunogenic, such as EA-D, EBNA-1, ZEBRA 
and VCA p18, in which anti-EBV antibodies against these proteins showed relatively 
strong associations with NPC (Cheng et al., 1993; Mathew et al., 1994; Gan et al., 1996; 
Chien et al., 2001; Dardari et al., 2001, 2008; Cheng, 2002; Chan et al., 2003; Karray et 
al., 2005; Fachiroh et al., 2006; Hu et al., 2007; Ji et al., 2007; Paramita et al., 2007; 
Tedeschi et al., 2007; Ng et al., 2009b; Abdulamir et al., 2010; Fachiroh et al., 2010; 
Paramita et al., 2011; Yu et al., 2011). By contrast, some EBV proteins are poorly 
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immunogenic, particularly the latency proteins, latent membrane proteins (LMP-1, 
LMP-2A) and BARF1, which are not useful biomarkers for NPC (Paramita et al., 2011). 
To date, however, immunoassays for EBV-associated NPC have not yet been 
standardized. (i) Although VCA/IgA by IFA is known as the ‘gold standard’ for NPC 
serology, it is in discord with a recent report that screened 2444 individuals from NPC 
multiplex families in Taiwan, showing that the performance of EBNA-1/IgA (by ELISA) 
was better than VCA/IgA (by both IFA and ELISA) (Yu et al., 2011). To maximize the 
clinical utility of VCA/IgA, long-term monitoring (about 15-year follow-up) of its 
fluctuating level in a suspected subject might be necessary (Chien et al., 2001; Ji et al., 
2007). This is because from the active follow-up, those who eventually developed NPC 
maintained high titers of VCA/IgA for three years before clinical onset (Ji et al., 2007). 
(ii) For ELISA, the EBV antigens were produced in various ways, ranging from the use 
of mammalian, insect, yeast and prokaryotic expression hosts to peptide synthesis 
(Cheng et al., 1991, 1993; Mathew et al., 1994; Dardari et al., 2001, 2008; Hu et al., 
2007; Paramita et al., 2007; Tedeschi et al., 2007; Paramita et al., 2011). (iii) Some 
studies used mixtures of two antigens or putative epitopes to enhance their ELISA 
performances (Fachiroh et al., 2006; Fachiroh et al., 2010). 
In addition, the diagnostic performances of serologic tests were varied among 
studies because of the discrepancies in study populations (sample size, ethnicity, and 
selection bias), assay setups, data analysis and interpretation, and lack of validation 
study. Therefore, the serological marker of choice and its cutoff value remain 
inconclusive (Fachiroh et al., 2010; Yu et al., 2011), hampering a comparison across 
ELISA studies. 
Serologic profiles in many populations from endemic and non-endemic regions 
have been investigated. However, ELISA study that reported its diagnostic accuracy on 
NPC in Malaysian Chinese is currently lacking. Although Mathew et al. (1994) and 
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Cheng et al. (1993) reported the diagnostic accuracies of ZEBRA/IgG (75% sensitivity, 
96.4% specificity) and synthetic peptides of EBNA-1/IgA (90.8% sensitivity, 92.9% 
specificity), respectively; they did not categorize study subjects by ethnicity (ethnicity is 
one of the major confounding factors). Despite the survival rate for early-stage patients 
is higher, most NPC cases in Malaysia were diagnosed at an advanced stage (Pua et al., 
2008; Zainal Ariffin Omar & Nor Saleha Ibrahim Tamin, 2011). Therefore, the present 
study intends to develop indirect ELISAs that can be used to screen the high-risk 
population in Malaysia in the future, using the immunogenic EBV proteins, EA-D, 
ZEBRA and VCA p18. We do not provide comparisons between our in-house ELISAs 
with commercial ELISA kits because the comparisons are part of an on-going study by 
our colleague. We believe that a meaningful comparison across ELISA studies can be 
done if all ELISA studies use standardized, Food and Drug Administration-approved 
ELISA kits in parallel, when applicable. 
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3.1. STUDY SUBJECTS 
3.1.1. Collection of plasma 
The ethical approval for this study was granted by the Medical Ethics 
Committee of UMMC. Volunteers were enrolled between September 2007 and April 
2011. 
Patients with biopsy-proven NPC were recruited at otorhinolaryngology clinic of 
UMMC during their follow-up appointments. A total of 165 prevalent cases (under 
remission) were recruited, including 148 Chinese (89.7%), 15 Malays (9.1%), and two 
Indians (1.2%). The ratios of male to female patients were exactly 3:1 and 2:1 in 
Chinese and Malays, respectively. The two Indians are males. 
Meanwhile, normal subjects were recruited during the blood donation campaigns 
organized by UMMC. A total of 658 normal subjects were recruited, including 334 
Chinese (229 males, 105 females), 154 Malays (99 males, 55 females), 168 Indians (100 
males, 68 females), and two Kadazans (males). 
A survey was performed to obtain their family history and individual 
information, i.e., age, gender, national identification, ethnicity and cancer staging (if 
applicable). With written consents, their blood samples were collected and managed as 
potentially infectious materials. About 3 ml of peripheral blood was withdrawn from 
each volunteer, transferred into blood collection tube containing K3EDTA, and 
temporarily kept on ice. Upon delivered to laboratory, it was centrifuged for 10 min at 
1,000 g at room temperature. Plasma was saved and kept at −20°C. 
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3.1.2. Individual matching 
To minimize bias, we performed individual matching based on age (within 5 
years), gender and ethnicity. Only Malaysian Chinese was selected for this study 
because the NPC cases of other ethnicity were insufficient.  
Before matching, 111 male patients (mean age, 55 years; range, 19–86 years) 
and 37 female patients (mean age, 51 years; range, 25–72 years) were eligible. Among 
the Malaysian Chinese normal subjects, three of them had a NPC-affected first-degree 
relative (n = 2) or spouse (n = 1) who is male and above 40-year-old. We excluded the 
three normal subjects with family history of NPC. Mixed parentage subjects were 
excluded as well. Hence, the normal subjects that eligible for matching were 227 males 
(mean age, 37 years; range, 16–59 years) and 104 females (mean age, 37 years; range, 
18–58 years). 
After matching, 120 case-control pairs were obtained. The case group was 
composed of 85 males (mean age, 51 years; range, 19–63 years) and 35 females (mean 
age, 50 years; range, 25–63 years). The control group was composed of 85 males (mean 
age, 47 years; range, 19–59 years) and 35 females (mean age, 45 years; range, 25–58 
years). 
 
3.2. PROTEIN EXPRESSION AND PURIFICATION 
3.2.1. Construction of prokaryotic expression vectors 
The target genes of EBV, strain B95-8 (GenBank: V01555) were subcloned 
from yeast expression vectors, pYES2.1 (generous gifts from Prof. Sam Choon Kook) 
into prokaryotic expression vector, pET102/TOPO-D (Invitrogen, USA). The sizes of 
empty pYES2.1 and pET102 vectors are 5882 bp and 6315 bp, respectively. The target 
genes are BMRF1 (1215 bp), BZLF1 (738 bp) and BFRF3 (531 bp), which encode full 
length EA-D, ZEBRA and VCA p18, respectively. Fusion protein produced by pET102 
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expression system contains N-terminal His-patch thioredoxin, and C-terminal V5 
epitope and 6×His tags. The N-terminal tag can increase translation efficiency and 
solubility of the fusion protein, whereas the C-terminal tags enable the immunodetection 
of the fusion protein; both His-patch thioredoxin and 6×His tags allow immobilized 
metal affinity chromatography (IMAC)-based purification (Lu et al., 1996; Terpe, 2003). 
The subcloning procedures are described in the following paragraphs. PCRs 
were performed using the pYES2.1 recombinant plasmids as DNA templates (Table 3.1, 
3.2, and 3.3). The PCR products were purified, mixed with vector and salt solutions, 
and incubated at room temperature for 5 min for TOPO ligation reaction (Table 3.4).  
 
Table 3.1. PCR working reaction. 
Reagent 
Working reaction 
Volume (µl) Concentration 
Sterile water 10.8; 11.3 - 
10×PCR buffer (with 20 mM MgCl2) 1.5 (1 mM MgCl2) 
dNTPs (10 mM) 0.3 0.2 mM 
Forward primer (10 µM) 0.6 0.4 µM 
Reverse primer (10 µM) 0.6 0.4 µM 
DNA polymerase (2.5 U/µl) 0.2 0.5 U/µl 
Plasmid; cell lysate 0.5; 1.0 50 ng/µl; uncharacterized 
Total volume 15  
Abbreviation: dNTP, deoxyribonucleotide triphosphate. 
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Table 3.2. Primer sequences for amplification EBV genes. 
EBV genes Primer (5′–3′) 
BMRF1 F: CACCATGGAAACCACTCAGACTCTC 
R: CTTATCGTCATCGTCAATGAGGGGGTTAAA 
BZLF1 F: CACCATGATGGACCCAAACTCGAC 
R: CTTATCGTCATCGTCGAAATTTAAGAGATC 
BFRF3 F: CACCATGGCACGCCGGCTGCCCAA 
R: CTTATCGTCATCGTCCTGTTTCTTACGTGC 
CACC (underlined) at the 5′ end of the forward primer (F) is required for TOPO 
directional ligation. 
CTTATCGTCATCGTC (underlined) at the 5′ end of the reverse primer (R) introduces 
an enterokinase recognition site at the upstream of the V5 epitope and 6×His tags to the 
fusion protein. 
 
Table 3.3. PCR cycling conditions. 
Cycle step Temperature (°C) Time Cycles 
Initial denaturation 94 5–15 min 1 
Denaturation 94 30 s  
25 Annealing 55 30 s 
Extension 72 30 s 
Final Extension 72 5–10 min 1 
 
Table 3.4. TOPO ligation reaction. 
Reagent Volume (µl) 
PCR product 4 
Salt solution (1.2 M NaCl, 0.06 M MgCl2) 1 
pET102 vector (15 to 20 ng/µl) 1 
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E. coli TOP10 competent cells (Invitrogen, USA) were transformed with the 
cloning reaction mixtures by heat shock method. In brief, 1 µl of the cloning reaction 
mixtures were added to 50 µl of the competent cells, gently mixed, and incubated on ice 
for 5 min. The cells were heat-shocked for 30 s at 42°C, returned to ice immediately, 
and grown in 250 µl of super optimal broth with catabolite repression (SOC) media at 
37°C for 1 h with moderate shaking (250 rpm). 
To select transformants, the bacterial cultures were grown in LB agar plate 
containing 100 µg/ml ampicillin at 37 °C overnight. Positive clones were identified by 
colony PCR (Table 3.1 and 3.3), using gene-specific forward primers (Table 3.2) and 
T7 reverse primer (a pET102 vector primer). Plasmids from positive clones were 
purified, followed by DNA sequencing. Molecular Evolutionary Genetics Analysis 4.0 
(Tamura et al., 2007) was used to analyze the sequencing results. 
 
3.2.2. Time course of IPTG-induced recombinant protein expression  
BL21Star (DE3) (Invitrogen, USA) was used as protein expression host. The 
competent cells of BL21Star (DE3) were transformed with the recombinant PET102 
plasmids using heat shock method (see Section 3.2.1). Their starter cultures were 
prepared in LB broths containing 100 µg/ml ampicillin and grown overnight at 37°C, 
250 rpm.  
The expression levels of the three target EBV proteins at varying time points 
after IPTG induction were investigated. In brief, 10 ml of fresh LB broths were seeded 
with 500 µl of starter cultures, and incubated at 37°C, 250 rpm. At mid-log phase, the 
10 ml of fresh cultures were divided into half to assign IPTG-induced and uninduced 
cultures. IPTG solution (0.1 M) was added to the designated cultures at a final 
concentration of 1 mM. 
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Once the inducer was added, 500 µl was withdrawn from each culture. The 
aliquots were centrifuged at maximum speed for 3 min. Supernatants were discarded. 
Pellets were labeled as zero-hour time point and kept at −20°C. Samplings were 
repeated at 1 h intervals until four-hour time point. The remaining cultures were 
incubated overnight, followed by final samplings for overnight time point. 
These E. coli samples were subjected to sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) (see Section 3.2.5). For Western blotting (see Section 
3.2.6), samples at four-hour time point were used. 
 
3.2.3. Auto-induction of recombinant protein expression 
Auto-induction was used to scale-up the productions of the target proteins with 
minimum effort (Studier, 2005). Starter cultures were prepared by growing the freshly 
transformed host cells in 10 ml of MDG non-inducing minimum media containing 100 
µg/ml ampicillin (Table 3.5 and 3.6), and grown overnight at 37°C, 250 rpm. 
Meanwhile, mock-transformed expression host was prepared, using media without 
antibiotic. It served as the negative control for this expression study. 
 Auto-induction was performed by growing the host cells (at 1000-fold dilutions 
of starter cultures) in 100 ml of ZYM-5052 media containing 100 µg/ml ampicillin 
(Table 3.5 and 3.6), and grown overnight at 37°C, 250 rpm. The auto-induced cultures 
were harvested for SDS-PAGE analysis and protein purification. 
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Table 3.5. Compositions of MDG and ZYM-5052 media.  
Component MDG ZYM-5052 
Tryptone - 1% 
Yeast extract - 0.5% 
Na2HPO4 25 mM 25 mM 
KH2PO4 25 mM 25 mM 
NH4Cl 50 mM 50 mM 
Na2SO4 5 mM 5 mM 
MgSO4 2 mM 2 mM 
1000×trace metals (see Table 3.5) 0.2× 0.2× 
Aspartate 0.25% (18.8 mM) - 
Glycerol - 0.5% (54 mM) 
Glucose 0.5% (27.8 mM) 0.05% (2.8 mM) 
α-lactose - 0.2% (5.6 mM) 
Adapted from Studier (2005). 
 
Table 3.6. Composition of 1000×trace metals for MDG and ZYM-5052 media.  
Trace metal Concentrations (μM) 
Fe 50 
Ca 20 
Mn, and Zn 10 (for each solution) 
Co, Cu, Ni, Mo, Se, and B 2 (for each solution) 
Adapted from Studier (2005). 
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3.2.4. IMAC-based purification by membrane adsorber 
We prepared the clarified lysates, i.e., the soluble fractions of cell extracts for 
protein purification under native conditions. In brief, the cell pellets from auto-induced 
cultures were resuspended in 15 ml of native purification buffer (50 mM NaH2PO4, 0.5 
M NaCl, pH 8.0), and sonicated for 4 times at 12×10 s with 10 s pauses at 250 W. The 
lysates were clarified by centrifugation at 12,000 g, 4°C for 1 h. 
A membrane-based purification device was assembled and charged. In brief, a 
0.45 µm syringe filter (25 mm diameter) was attached to the inlet (female luer lock) of 
two connecting units of Sartobind IDA (iminodiacetic acid) 75 (Sartorius) to prevent 
clotting. The bed volume of this device is about 4.2 ml. Using a luer lock syringe, this 
device was equilibrated with 10 ml  of equilibration buffer (0.1 M CH3COONa, 0.5 M 
NaCl, pH 4.5), and charged with 10 ml of cobalt solution (equilibration buffer 
containing 0.1 M CoCl2). To minimize the leaching of cobalt ion, the device was 
flushed with 10 bed volumes of equilibration buffer, followed by 10 bed volumes of 
native purification buffer. 
The clarified lysates were loaded. About 1 ml of fractions were collected 
continuously until the end of elution. Unbound materials were washed away by 10 bed 
volumes of native wash buffer (20 mM sodium phosphate, 0.5 M NaCl, 10 mM 
imidazole, pH 8.0), followed by elution at 250 mM imidazole by native elution buffer 
(20 mM sodium phosphate, 0.5 M NaCl, 250 mM imidazole, pH 8.0). 
 
 
 
 
 
 
CHAPTER 3. MATERIALS AND METHODS 
26 
 
3.2.5. SDS-PAGE 
Discontinuous Tris-glycine gels were prepared using Mini-PROTEAN 3 (Bio-
Rad, USA) (Table 3.7). Samples were treated with Laemmli sample buffer (62.5 mM 
Tris-HCl buffer (pH 6.8), 10% (v/v) glycerol, 2% (w/v) SDS, 0.01% (w/v) bromophenol 
blue and 5% (v/v) ß-mercaptoethanol), boiled for 10 min, and clarified by centrifugation 
at maximum speed for 5 min. 
Supernatants of the samples (10 µl each) were applied to the vertical gels, and 
electrophoresed at 120 V for 90 min in running buffer (25 mM Tris, 192 mM glycine, 
0.1% SDS, pH 8.3). 
The gels were stained with staining solution (0.2% Coomassie brilliant blue R-
250, 40% (v/v) methanol and 10% (v/v) acetic acid) for overnight. Excessive dye was 
removed by placing the gel in destaining solution (5% (v/v) methanol, 7% (v/v) acetic 
acid). The gels were then digitized on a flatbed scanner. 
 
Table 3.7. Composition of discontinuous SDS-PAGE gel. 
Reagent 
Volume (µl) 
10% separating gel  4% stacking gel 
Acrylamide/bis (30% T, 2.67% C) (w/v) 2670 665 
4×gel buffer  2000 (1.5 M  Tris-Cl, pH 8.8) 
1250 (0.5 M  
Tris-Cl, pH 6.8) 
10% (w/v) SDS 80 50 
Sterile water 3250 3000 
10% (w/v) ammonium persulfate 120 50 
N,N,N',N'-tetramethylethylenediamine  8 5 
Abbreviation: SDS, sodium dodecyl sulfate. 
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3.2.6. Western blotting 
Protein bands in SDS-PAGE gels were transferred to 0.45 µm PVDF 
(poly(vinylidene difluoride)) membranes by Mini Trans-Blot cell (Bio-Rad, USA) at 50 
V for 1 h 30 min. Towbin buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, 20% 
methanol, pH 8.3) was used in the wet/tank blotting system. 
The blots were blocked with milk blocking solution (KPL, USA) at 1:10 in 
sterile water for 1 h. Tris-buffered saline-Tween-20 buffer (TBS-T: 50 mM Tris, 150 
mM NaCl, 0.05% (v/v) Tween-20, pH 7.6) were used for washing and antibody dilution. 
The blots were washed three times with TBS-T buffer, and incubated with anti-V5 
antibody, alkaline phosphatase (AP) conjugate (Invitrogen, USA) at 1:5,000 for 1 h.  
After another three wash steps, the blots were developed with BCIP/NBT (5-
bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium) one-component 
phosphatase substrate (KPL, USA). The color development was halted by rinsing the 
blots with sterile water, and air-drying. The blots were digitized on a flatbed scanner. 
For purified proteins, additional immunodetections were performed using EBV 
antigen-specific monoclonal or polyclonal antibodies (Table 3.8). Their secondary 
antibodies was goat anti-mouse IgG AP (Santa Cruz, USA) or rabbit anti-goat IgG 
Reserve AP (KPL, USA) antibodies, at 1:10,000. 
 
Table 3.8. EBV antigen-specific monoclonal or polyclonal antibodies. 
EBV 
antigen 
Primary antibody 
Clone Host Dilution 
EA-D Anti-EBV EA-D-p52/50, clone R3 (Chemicon, USA) Mouse 1:1,000 
ZEBRA Anti-EBV Bam HI Z, clone BDI506 (Abcam, USA) Mouse 1:200 
VCA p18 Anti-p18 of VCA, polyclonal (Virostat, USA) Goat 1:2,000 
Abbreviations: EBV, Epstein-Barr virus; EA-D, early antigen-diffuse; ZEBRA, Z-
encoded broadly reactive activator; VCA, viral capsid antigen. 
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3.2.7. Quantification of purified proteins 
Bradford assay was performed in a microplate format. Bovine serum albumin 
(BSA) standard (1.39 mg/ml) was diluted from 0.1 to 0.5 mg/ml with sterile water to 
final volumes of 10 µl in duplicates. The pooled, eluted fractions from protein 
purification were diluted at 1:10 and 1:20 in duplicates.  
The dye solution (Bio-Rad, USA) was diluted at 1:5 with sterile water, filtered, 
and added to protein solutions, 200 µl per well. The microplate was gently mixed, and 
incubated at room temperature for 5 min. Absorbance at 595 nm (A595) was measured. 
Protein concentrations were estimated from a BSA standard curve. 
 
3.3. DEVELOPMENT OF INDIRECT ELISAS 
3.3.1. Selection of blocking agent 
Blocking agent is needed for indirect ELISA in order to block the remaining 
binding surface of a solid phase after antigen immobilization (Crowther, 2009). To 
choose a blocking agent for our ELISA serology, we examined the effectiveness of two 
major groups of blocking agents, namely (i) commonly used blocking agents, fatty acid 
free BSA (Sigma, USA), nonfat dry milk (NFDM) (KPL, USA) and Hammarsten grade 
casein (Merck, Germany); and (ii) synthetic polymers, Ficoll PM400 (Sigma, USA), 
fully hydrolyzed poly(vinyl alcohol) (PVA) (Merck, Germany) and poly(vinyl 
pyrrolidone) (PVP) (Sigma, USA) (Rodda & Yamazaki, 1994; Studentsov et al., 2002; 
Huber et al., 2009). Approximate molecular weights for Ficoll (400,000), PVA (15,000) 
and PVP (10,000) are indicated in parentheses.   
The synthetic polymers were prepared in ELISA compatible diluents, 
1×phosphate-buffered saline (1×PBS: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 
1.76 mM KH2PO4, pH 7.4) and coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 
9.6) (Huber et al., 2009). BSA and casein were prepared by standard protocols, using 
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1×PBS and alkaline hydrolysis, respectively (Pratt & Roser, 2010); 2% (w/v) NFDM 
stock solution was diluted at 1:20 in sterile water, according to the manufacturer's 
recommendation. Except NFDM, the concentration used for all blocking buffers was 4% 
(w/v), because most blocking agents were claimed to be effective within 5% (w/v) in 
ELISA studies. 
This experiment is a modification of the routine ELISA serology (see Section 
3.3.5, Table 3.8 versus 3.9), namely ZEBRA/IgG and VCA p18/IgG in order to estimate 
the sample backgrounds. All empty wells of Maxisorp poly(styrene) microplates  (Nunc, 
Denmark) were directly coated with blocking agents, except for wells assigned to 
substrate control 2 (SC2) (Table 3.8) (True, 2009). Thus samples from 12 case-control 
pairs were assayed in the absence of immobilized antigen. Full assay controls here 
consist of substrate control 1 (SC1), SC2, conjugate control (CC), strong positive (C++), 
moderately positive (C+) and negative (C−) controls (Table 3.9) (True, 2009).  
 
Table 3.9. Experimental setups for assay controls used in the comparison of blocking 
agents for ELISA serology.a 
Assay control 
Incubation step 
Coating Primary antibody Secondary antibody 
 SC1 Blocking buffer 
Dilution buffer 
Blocking buffer 
 SC2 Coating buffer Dilution buffer 
 CC 
Blocking buffer Goat anti-human IgG, HRP conjugate 
 C++  C++ 
 C+  C+ 
 C−  C− 
Adapted from True (2009). 
a Coating buffer is 15 mM Na2CO3, 35 mM NaHCO3, pH 9.6; dilution buffer is 1×PBS 
containing 0.05% (v/v) Tween-20, pH 7.4. 
Abbreviations: ELISA, enzyme-linked immunosorbent assay; SC1, substrate control 1; 
SC2, substrate control 2; CC, conjugate control; C++, strong positive control; C+, 
moderately positive control; C−, negative control; IgG, immunoglobulin G; HRP, 
horseradish peroxidase; PBS, phosphate-buffered saline. 
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It should be noted that only coated blocking agent and buffer residuals remain in 
SC1 prior to the addition of substrate solution, hence SC1 serves to validate the 
condition of quantitative substrate system. By contrast, only buffer residuals remain in 
SC2 prior to the addition of substrate solution. Therefore, the reading difference 
between SC1 and SC2 serve to monitor the non-enzymatic reactions between a blocking 
layer and the components of substrate system, if any. CC serves to monitor the 
nonspecific binding of conjugate to the solid phase upon blocking. C++, C+ and C− 
assay controls are three in-house plasma pools determined by checkerboard titrations 
(see Section 3.3.4).   
 
3.3.2. Grid experiments 
We performed grid experiments to optimize the blocking conditions of PVA in 
the absence of immobilized antigen (see Figure 3.1, Section 3.3.1 and 3.3.5). The 
kosmotropes and pHs of PVA solutions were given by the diluents used, 1×PBS and 
coating buffer. PVA blocking buffers were serially diluted from 4% to 0.25% (w/v), to 
include both 1% and 0.5% (w/v) that were shown to be effective in other immunoassays 
(Huber et al., 2009; Rodda & Yamazaki, 1994; Studentsov et al., 2002). The blocking 
steps were performed accordingly, under three common incubation conditions of ELISA, 
(i) static incubation at 4°C overnight, and shaking incubation for 2 h at (ii) 37°C and (iii) 
room temperature (Huber et al., 2009). Plasma pools of NPC (n = 4) and normal (n = 4) 
subjects were assayed at 1:100, 1: 400 and 1: 1,600. Different sets of plasma were used 
in Section 3.3.1, 3.3.2, and 3.3.3. 
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 PVA (% w/v) in 1×PBS (row A to D) or coating buffer (row E to H) 
 4 2 1 0.5 0.25 Diluent 4 2 1 0.5 0.25 Diluent 
 1 2 3 4 5 6 7 8 9 10 11 12 
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1:100 A
1:400 B
1:1,600 C
Dilution 
buffer D Plasma pool from Plasma pool from  
1:100 E NPC patients, n = 4 normal subjects, n = 4 
1:400 F 
1:1,600 G
Dilution 
buffer H
 
Figure 3.1. Microplate design for grid experiments to represent the possible 
combinations of PVA blocking buffers, and plasma pools from NPC patients (n = 4) and 
normal subjects (n = 4). Diluent for PVA is either 1×PBS (row A to D) or coating buffer 
(row E to H). Dilution buffer used to dilute the two plasma pools was 1×PBS containing 
0.05% (v/v) Tween-20, pH 7.4. Gray areas indicate rows and columns of a microplate. 
 
3.3.3. Comparison of signal-to-noise ratios (SNRs) 
To estimate SNRs, additional 24 NPC patients were assayed with and without 
immobilized antigen (ZEBRA), using indirect ELISA approaches as described in both 
Section 3.3.1 and 3.3.5. Blocking using (i) NFDM at 1:20 in sterile water 
(manufacturer's recommendation), and 4% (w/v) PVA in (ii) 1×PBS or (iii) coating 
buffer for 2 h at room temperature was performed accordingly. 
The signals of assayed samples were recorded from solid phases that coated with 
antigen and blocked with blocking buffers. The noises of assayed samples (sample 
backgrounds) were estimated from solid phases that blocked with blocking buffers, but 
not coated with antigen. 
Using coin 1.0-18 package (Hothorn et al., 2006, 2008) for R 2.13.0 (R 
Development Core Team, 2011), Wilcoxon signed rank test (two-sided) was used to 
compare the paired data, i.e., signals and noises for 24 NPC samples. p-value greater 
than 0.05 indicates statistical significance. 
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3.3.4. Checkerboard titrations 
To optimize the key reagents (concentrations of antigens, plasma, and conjugate) 
for ELISA serology (see Section 3.3.5), checkerboard titrations were performed in two 
stages (Crowther, 2009). Only two reagents can be titrated at a single stage. 
At stage 1, EBV antigens were titrated against C++, C+ and C− (Figure 3.2A). 
The in-house assay controls were used because they could represent strong positive, 
moderately positive, and negative plasma samples. At stage 2, the three assay controls 
were titrated against conjugate at optimum dilutions of EBV proteins that obtained from 
stage 1 (Figure 3.2B). 
Using drc 2.1-4 (Ritz & Streibig, 2005) and qpcR 1.3-4 (Ritz & Spiess, 2008) 
packages for R 2.13.0 (R Development Core Team, 2011), the endpoint titration curves 
of C++ and C+ were fitted with four-parameter logistic function in order to determine if 
the blocking buffer (4% (w/v) PVA in coating buffer) is compatible with other ELISA 
reagents, i.e., signal exhibits a sigmoidal relationship with the concentration of primary 
antibody in plasma.  
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B Plasma Dilution (column 1 to 11) 
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Figure 3.2. Microplate layouts for checkerboard titrations. (A) At stage 1, coating step, 
column 1 to 11 received a serially diluted EBV protein; column 12 received coating 
buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) only. During primary antibody 
incubation, row A to G received a serially diluted assay control, C++, C+ or C−; row H 
received dilution buffer (1×PBS containing 0.05% (v/v) Tween-20, pH 7.4) only. (B) At 
stage 2, coating step, all wells receive the optimally diluted EBV protein determined 
from stage 1. During primary antibody incubation, column 1 to 11 received a serially 
diluted assay control, C++, C+ or C−; column 12 received dilution buffer only. During 
secondary antibody incubation, row A to G received a serially diluted conjugate; row H 
received dilution buffer only. Gray areas indicate the rows and columns of microplates. 
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3.3.5. Serologic tests 
The purified EBV proteins served as antigen for indirect ELISAs. Microplates 
were coated with antigen, except for wells assigned to SC1 and CC (Table 3.9) (True, 
2009). The plates were washed three times with wash buffer (1×PBS, 0.1% (v/v) 
Tween-20, pH 7.4). 
Remaining active sites in all wells were blocked with blocking buffer, 200 µl per 
well, followed by shaking incubation for 2 h at room temperature. The three wash steps 
were repeated. Dilution buffer (1×PBS, 0.05% (v/v) Tween-20, pH 7.4) was used to 
dilute plasma at 1:400. All plasma samples were assayed in triplicates, 50 µl per well. 
Full assay controls that consist of blank, SC1, CC, C++, C+ and C− were assayed in 
quadruplicates (Table 3.10) (True, 2009). Thus we screened up to 24 samples per 
microplate. 
 
Table 3.10. Experimental setups for assay controls used in ELISA serology.a 
Assay control 
Incubation step 
Coating Blocking Primary antibody Secondary antibody 
 SC1 Coating 
buffer 
Blocking 
buffer 
Dilution buffer 
Blocking buffer 
 CC 
Goat anti-human IgG, 
HRP conjugate 
 Blank 
Antigen 
 C++  C++ 
 C+  C+ 
 C−  C− 
Adapted from True (2009). 
a Coating buffer is 15 mM Na2CO3, 35 mM NaHCO3, pH 9.6; dilution buffer is 1×PBS 
containing 0.05% (v/v) Tween-20, pH 7.4. 
Abbreviations: ELISA, enzyme-linked immunosorbent assay; SC1, substrate control 1; 
CC, conjugate control; C++, strong positive control; C+, moderately positive control; 
C−, negative control; IgG, immunoglobulin G; HRP, horseradish peroxidase; PBS, 
phosphate-buffered saline. 
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It should be noted that blank serves to check the non-specific binding of 
conjugate to the solid phase upon antigen immobilization and blocking. To remove 
loosely bound materials, we used Tween-20, a detergent that can also act as blocking 
agent (Esser, 2010), in both dilution buffer and wash buffer. Tween-20 may (i) replace 
loosely bound antigen and blocking agent after coating and blocking steps, respectively; 
and (ii) bind to the hydrophobic moieties of blocking agent, increasing the surface 
polarity of a solid phase. Both mechanisms may suppress nonspecific binding and 
improve the selectivity of indirect ELISA. 
After shaking incubation of diluted plasma for 2 h at room temperature, the 
microplate was washed four times with wash buffer. Goat anti-human IgG, HRP 
conjugate (KPL, USA) at 1:20,000 was added to the microplates, 50 µl per well, 
followed by shaking incubation for 1 h at room temperature. The four wash steps were 
repeated. 
SureBlue Reserve TMB (3,3',5,5'-tetramethylbenzidine) substrate (KPL, USA) 
was added, 100 µl per well, followed by static incubation for 10 min at room 
temperature in the dark. TMB BlueStop solution (KPL, USA) was then added 
immediately, 100 µl per well. A630 was measured. To normalize the absorbance values 
between microplates, percentage positivity (PP) was used to express the ELISA data 
(Wright et al., 1993): 
PP = (A630 of a sample / A630 of C++ from the same microplate) × 100                          (1) 
In the present study, we wanted to classify the study subjects correctly into 
disease (NPC) and non-disease (normal) using the EBV serologic tests. To assess the 
diagnostic accuracy of EBV serologic tests, receiver operating characteristics (ROC) 
analyses of the serologic tests were done using ROCR package 1.0-4 (Sing et al., 2005) 
for R 2.13.0 (R Development Core Team, 2011). The optimal cutoff value−a cutoff 
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value with the highest Youden's score (Bewick et al. (2004); see Equation (2))−for each 
EBV serologic test was obtained from the ROC analyses, in which one is predicted to 
have NPC (test positive) if his or her PP value (normalized anti-EBV IgG level) is 
higher than the optimal cutoff value. The results of each EBV serologic test can be 
presented in a confusion matrix (e.g., Table 3.11). 
  
Table 3.11. Confusion matrix for the outcome of each EBV serologic test. 
 NPC 
Test Present Absent 
Positive True positive False positive 
Negative False negative True negative 
 
Youden's index = sensitivity + specificity – 1                                                                 (2) 
Sensitivity = true positive / (true positive + false negative)                                             (3) 
Specificity = true negative / (false positive + true negative)                                            (4) 
Accuracy = (true positive + true negative) / (true positive + true negative + false 
positive + false negative)                                                                                                  (5) 
 
Performance characteristics such as sensitivity, specificity and accuracy of each 
EBV serologic test can be calculated based on the confusion matrix. Sensitivity is the 
proportion of those who are correctly classified as NPC cases by the EBV serologic test 
in total NPC cases (see Equation (3)). Specificity is the proportion of those who are 
correctly classified as normal subjects by the EBV serologic test in total normal subjects 
(see Equation (4)). On the other hand, accuracy is the proportion of those who are 
correctly classified as NPC and normal subjects by the EBV serologic test in total study 
subjects (see Equation (5)). 
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Because the ELISA data are continuous variables, a range of cutoff values can 
be obtained from the ROC analyses, in which sensitivity and specificity can be 
calculated based on the outcome of each cutoff value. To construct the ROC curve for 
each EBV serologic test, sensitivity (y-axis) was plotted in function of 1 – specificity 
(x-axis), illustrating the trade-off between sensitivity and specificity across varying 
cutoff values in the binary classification process. 
Areas under the ROC curves (AUCs), a performance characteristic that is 
independent of the cutoff value, were calculated by trapezoidal rule. The guidelines to 
interpret AUC (Swets, 1988; Zweig et al., 1992; Zweig & Campbell, 1993; Levinson, 
2010) are: (i) maximum and minimum AUC scores are 1.0 (perfect classification) and 
0.5 (random classification), respectively. (ii) AUC scores of 0.5–0.7, 0.7–0.9, and above 
0.9 represent low, intermediate, and high classification accuracies, respectively. (iii) 
AUC score of below 0.7 shows weak association of a marker with the disease. 
To compare the performance between the EBV serologic tests, Mann-Whitney 
U-statistic implemented in StAR (statistical analysis of ROC curves) web server version 
(Vergara et al., 2008; http://protein.bio.puc.cl/star/roc_analysis.php) was used for 
pairwise comparison of the AUC scores. p-value greater than 0.05 indicates statistical 
significance. 
 
3.3.6. Assay reproducibility 
The reproducibility of ELISA serology, i.e., inter-assay and intra-assay 
precisions were calculated from the quadruplicates of full assay controls across routine 
runs (n = 10) on different days (see Section 3.3.5). 
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Figure 3.3. Workflow of experimental procedures in the present study. 
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CHAPTER 4. RESULTS 
 
4.1. STUDY SUBJECTS 
 Over a 3.5-year period in sample collection, a total of 165 prevalent cases of 
NPC were enrolled. For Chinese patients, the highest frequencies of both male and 
female cases were in the 50–59 age group (Table 4.1), which was in agreement with 
age-specific incidence curves (Figure 2.2). Also, we observed familial clustering of 
NPC, in which 23 NPC patients (all Chinese) had family history of NPC: five of them 
had two NPC-affected first-degree relatives, 16 of them had a NPC-affected first-degree 
relative, and two of them had a NPC-affected second-degree relative. NPC was most 
prevalent in Chinese (n = 148), which comprised of 89.7% (148/165) total cases. In 
particular, 14.2% (21/148) Chinese cases were familial NPC (had at least one NPC-
affected first-degree relative). Chinese males (n = 111) were 3-fold more prevalent than 
females (n = 37). 
In our pilot survey of prevalence, two of 334 Chinese normal subjects had a 
first-degree family member affected by NPC. The prevalence of family history of NPC 
among the Chinese controls was 0.6% (2/334). None of the controls of other ethnicity (n 
= 324) had family history of NPC. 
 
Table 4.1. Prevalent cases of NPC for Chinese by age and gender. 
Age 10–19 20–29 30–39 40–49 50–59 60–69 ≥70 
Male (n) 1 0 6 28 37 27 12 
Female (n) 0 1 4 10 17 3 2 
Abbreviation: NPC, nasopharyngeal carcinoma. 
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4.2.2. Time course of IPTG-induced protein expression 
The target proteins produced by this prokaryotic expression system were tagged 
with His-patch thioredoxin at N-terminus, V5 and 6×His at C-terminus. 
To express the target proteins, the recombinant PET102 plasmids were 
transformed into prokaryotic expression host, BL21 Star (DE3). IPTG was used as 
artificial inducer for the T7 lac promoter containing plasmid for protein expression. 
To harvest the target proteins at optimum levels, we monitored the expression 
cultures at varying time points by SDS-PAGE (Figure 4.3). Both ZEBRA (Figure 4.3B) 
and VCA p18 (Figure 4.3C) were expressed at high levels starting from two-hour IPTG 
induction. However, the expression level of EA-D was low across the time points 
(Figure 4.3A). 
Western blotting was performed using the whole cell extracts of E. coli from the 
IPTG-induced cultures at four-hour time point. Anti-V5 antibody was used to probe the 
fusion proteins. The blots showed that the V5-tagged proteins are present at the 
expected molecular weights as suggested by SDS-PAGE (EA-D, 65 kDa; ZEBRA, 55 
kDa; VCA p18, 40 kDa) (Figure 4.4), indicating that the EBV proteins were expressed 
as fusion proteins in full lengths. 
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Figure 4.3. Time course of IPTG-induced expression of recombinant EBV proteins in 
BL21Star (DE3). SDS-PAGE gels show the migration patterns of whole cell extracts of 
IPTG-induced (+) and uninduced (−) E. coli samples expressing (A) EA-D (65 kDa), (B) 
ZEBRA (55 kDa), and (C) VCA p18 (40 kDa). M denotes PageRuler prestained protein 
ladder (Fermentas, Canada). ON denotes overnight. 
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Figure 4.4. Western blots show the protein bands of V5-tagged EA-D (65 kDa) (1), 
ZEBRA (55 kDa) (2) and VCA p18 (40 kDa) (3), which were detected from E. coli 
samples after a four-hour IPTG induction, using anti-V5 antibody. M denotes PageRuler 
prestained protein ladder (Fermentas, Canada). 
 
4.2.3. Auto-induction of recombinant protein expression 
 It is costly to purify EA-D with low expression level because its culture work 
needs to be several-fold more than the work for ZEBRA and VCA p18. We therefore 
adopted an alternative expression strategy, i.e., auto-induction (see Section 3.2.3) 
(Studier, 2005). MDG non-inducing media were used to prepare starter cultures for the 
expression hosts. Auto-induction was performed by seeding ZYM-5052 auto-induction 
media with the MDG starter cultures. 
The recombinant EA-D protein was expressed at a higher level compared with 
that of IPTG induction (Figure 4.5A, left panel versus Figure 4.3A). The expression 
levels of ZEBRA and VCA p18 by both induction methods were comparable (Figure 
4.3B and 4.3C versus Figure 4.5A, left panel). Therefore, auto-induction was used to 
express the recombinant EBV proteins in the subsequent scale-up cultures (in 100 ml 
volumes) for protein purification. 
 
4.2.4. IMAC-based purification by membrane adsorber 
 Cobalt-charged membrane adsorbers were employed to purify the His-tagged 
proteins. Under native conditions, these target proteins were eluted by imidazole from 
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the IMAC-based device. SDS-PAGE analysis showed a single protein band for each 
pooled, purified fraction (Figure 4.5A, right panel). The protein bands were then 
identified by both anti-V5 antibody, and specific monoclonal or polyclonal antibodies in 
Western blotting (Figure 4.5B), suggesting that all three target proteins have been 
expressed and purified from E. coli. 
The yields of purified EA-D, ZEBRA and VCA p18 from 100 ml cultures were 
2.03, 1.96 and 2.87 mg, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Auto-induced expression of recombinant EBV proteins in BL21 Star (DE3) 
and IMAC-based purification of target proteins. (A) SDS-PAGE gel (left) shows the 
migration patterns of the whole cell extracts of E. coli samples expressing EA-D (65 
kDa) (1), ZEBRA (55 kDa) (2) and VCA p18 (40 kDa) (3). SDS-PAGE gel (right) 
shows the migration patterns of the pooled fractions of EA-D (4), ZEBRA (5) and VCA 
p18 (6) after purification. (B) Western blots show the protein bands of recombinant EA-
D (1, 2), ZEBRA (3, 4) and VCA p18 (5, 6), which were detected from the pooled 
fractions, using anti-V5 antibody (odd-numbered lanes), and EBV antigen-specific 
monoclonal or polyclonal antibodies (even-numbered lanes). N denotes the negative 
control for protein expression, i.e., the mock-transformed BL21Star (DE3). M denotes 
PageRuler prestained protein ladder (Fermentas, Canada).  
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4.3. DEVELOPMENT OF INDIRECT ELISAS 
4.3.1. Selection of blocking agent 
The purified proteins served as antigens in indirect ELISAs. Because indirect 
ELISA is very sensitive, antigen is often coated at low concentration. The remaining 
active sites, which account for the majority of the binding surface, are then blocked with 
a blocking buffer. Therefore, the blocking agent used should prevent nonspecific 
binding of materials from primary (diluted plasma) and secondary antibodies. Only non-
immunogenic blocking agent that adsorbed tightly on the solid phase can provide low 
background. 
To choose a suitable blocking agent, we determined the effectiveness of 
commonly used (BSA, NFDM and casein) and synthetic polymer (Ficoll, PVA and PVP) 
blocking agents (see Section 3.3.1). Backgrounds for 12 pairs of case-control samples 
were estimated from the microplates that blocked with different blocking buffers in the 
absence of immobilized antigen, because the lower the sample backgrounds, the more 
effective the blocking, and hence the higher the assay reliability. 
Here, the sample backgrounds provided by commonly used blocking agents 
were relatively higher than those provided by synthetic polymer blocking agents (Table 
4.2). Exceptionally high sample backgrounds were observed when NFDM was used as 
blocking agent. Only Ficoll (1×PBS and coating buffer) and PVA (coating buffer) were 
able to provide relatively low sample backgrounds with small variations. Also, sample 
backgrounds that correspond to synthetic polymers at 4% (w/v) in coating buffer were 
relatively lower than those in 1×PBS.  
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Table 4.2. Sample backgrounds (12 NPC and 12 normal subjects) provided by different 
blocking buffers. 
Blocking buffer 
A630  
Maximum Minimum Range Mean ± SD CV (%) 
BSA 0.56 0.16 0.40 0.23 ± 0.09 41.6  
NFDM 2.83 0.18 2.66 0.86 ± 0.82 95.4  
Casein 0.64 0.18 0.47 0.27 ± 0.10 38.6  
Ficoll in 1×PBS 0.26 0.17 0.10 0.19 ± 0.02 11.2  
Ficoll in coating buffer 0.24 0.17 0.08 0.19 ± 0.02 9.0  
PVA in 1×PBS 0.44 0.15 0.29 0.25 ± 0.07 29.2  
PVA in coating buffer 0.32 0.17 0.15 0.22 ± 0.04 17.7  
PVP in 1×PBS 0.57 0.16 0.40 0.28 ± 0.09 31.8  
PVP in coating buffer 0.46 0.17 0.29 0.24 ± 0.06 25.5  
Abbreviations: A630, absorbance at 630 nm; SD, standard deviation; CV, coefficient of 
variation; BSA, bovine serum albumin; NFDM, nonfat dry milk; PBS, phosphate-
buffered saline; PVA, poly(vinyl alcohol); PVP, poly(vinyl pyrrolidone). 
 
4.3.2. Grid experiments  
Because PVA was effective for blocking and the cheapest among the tested 
blocking agents, we further examined the optimum blocking conditions of PVA using 
grid experiments (see Section 3.3.2). At different polymer concentrations, compositions 
of kosmotrope(s), temperatures, and pHs, we estimated the backgrounds for plasma 
pools of NPC (n = 4) and normal (n = 4) subjects at different dilutions, because sample 
backgrounds should be considerably low and close to each other, regardless of case-
control status and dilution factor. 
In Figure 4.6: (i) decreasing backgrounds were observed with increasing PVA 
concentration, in which 4% (w/v) PVA provides the lowest backgrounds. The 
concentrations of PVA at 0.5% and 1% (w/v), which were shown to be effective in 
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previous studies (Huber et al., 2009; Rodda & Yamazaki, 1994; Studentsov et al., 2002), 
were insufficient for blocking in our study. (ii) 1×PBS was a better diluent than coating 
buffer for PVA below 2% (w/v), which is in agreement with a recent finding (Huber et 
al., 2009). However, the effects of diluents were not obvious for 4% (w/v) PVA. 
 
 
 
Figure 4.6. Trellis plot shows the blocking effectiveness of varying PVA concentrations 
at different compositions of kosmotrope(s), incubation temperatures and pHs, obtained 
from the indirect ELISA results for plasma pools of NPC (n = 4) and normal (n = 4) 
subjects at different dilutions. The grid experiments were performed in the absence of 
immobilized antigen. Alphabets on the figure annotate the plasma dilutions as follows: 
A, B and C correspond to NPC plasma pool at 1:100, 1: 400 and 1: 1,600, respectively, 
whereas X, Y and Z correspond to normal plasma pool at 1:100, 1: 400 and 1: 1,600, 
respectively. Pink and blue alphabets represent backgrounds (A630 values) for the diluted 
plasma, provided by the PVA blocking layers assembled in 1×PBS and coating buffer 
(15 mM Na2CO3, 35 mM NaHCO3, pH 9.6), respectively. 
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4.3.3. Comparison of SNRs 
Additional 24 NPC samples were included to seek the best diluent for PVA (see 
Section 3.3.3). Signals and backgrounds for the samples were obtained from the assays 
in the presence and absence of ZEBRA, respectively. We chose ZEBRA as antigen for 
this experiment because circulating anti-ZEBRA IgG is one of the most promising anti-
EBV IgG biomarkers for NPC (Dardari et al., 2001; Mathew et al., 1994), and therefore 
the 24 NPC samples should give strong signals. The blocking effectiveness of (i) 
NFDM, and 4% (w/v) PVA in (ii) 1×PBS and (iii) coating buffer was compared in 
terms of backgrounds and SNRs. The SNRs of individual samples were estimated by 
dividing their signals by backgrounds. 
When using NFDM as blocking agent, the distribution for signals obtained from 
24 NPC samples were completely overlapped with the distribution for their 
backgrounds (Figure 4.7) (Wilcoxon signed rank test: z = 1.97, p = 0.049, r = 0.40; in 
which z corresponds to z-score, p corresponds to p-value, r corresponds to Pearson's 
correlation coefficient, as an effect size measure). By contrast, when using 4% (w/v) 
PVA as blocking agent, the distribution for signals did not overlap with the distribution 
for backgrounds (Wilcoxon signed rank test: z = 4.29, p = 1.19×10−7, r = 0.87). Here, 
sample backgrounds that correspond to 4% (w/v) PVA in coating buffer (A630, 0.22 ± 
0.06) were relatively lower than those in 1×PBS (A630, 0.28 ± 0.07), suggesting that the 
data from Table 4.2 and Figure 4.7 are in agreement. 
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Figure 4.7. Box plots shows the signals (□) and noises (■) of 24 NPC samples in 
ELISAs using NFDM (A), and PVA in 1×PBS (B) and coating buffer (15 mM Na2CO3, 
35 mM NaHCO3, pH 9.6) (C) as blocking buffers. The signals of assayed samples were 
recorded as routine indirect ELISA, from solid phases that coated with antigen (ZEBRA) 
and blocked with blocking buffers. The noises of assayed samples (sample backgrounds) 
were estimated from solid phases blocked with blocking buffers, but not coated with 
antigen. The box plots should show distinct gaps between signals and noises. p-values 
were obtained from Wilcoxon signed rank test on the paired data, i.e., signals and noises 
for 24 NPC samples. 
 
For SNRs, blocking with 4% (w/v) PVA in coating buffer was 4.26-fold, on 
average, higher than blocking with NFDM. Also, it was 1.25-fold, on average, higher 
than blocking with 4% (w/v) PVA in 1×PBS. Therefore, 4% (w/v) PVA in coating 
buffer was chosen for the subsequent experiments. 
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4.3.4. Checkerboard titrations 
 To optimize reagents in ELISA serology, checkerboard titrations were 
performed (see Section 3.3.4). Four-parameter logistic function was used to fit the 
endpoint titration curves for C++, C+ and C− at optimum reagents (Figure 4.8). Here, 
coefficients of determination, R2 above 0.99 were obtained. 
 
 
Figure 4.8. Endpoint titration curves for C++ ( ), C+ ( ) and C− ( ), obtained from 
the checkerboard titrations of (A) EA-D/IgG, (B) ZEBRA/IgG and (C) VCA p18/IgG 
indirect ELISAs. C++, C+ and C− denote strong positive, moderate positive and 
negative assay controls, respectively. The R2 of the four-parameter logistic curves are 
shown in parentheses. 
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4.3.5. Serologic tests 
Based on the optimized setup, samples from 120 age- and gender-matched, case-
control pairs were subjected to EA-D/IgG, ZEBRA/IgG and VCA p18/IgG indirect 
ELISAs. The ELISA data were analyzed by ROC. Appendix A, B and C show the 
outputs of the ROC analyses, including (i) lists of cutoff values for the EBV serologic 
tests, in which each cutoff value shows the number of study subjects with test positive, 
and (ii) sensitivity, specificity and Youden's index calculated for each cutoff value (see 
Equation (3), (4) and (5), respectively). Sensitivity was plotted against 1 − specificity, 
generating ROC curves for the EBV serologic tests (Figure 4.9). The cutoff values with 
the highest Youden's score were chosen, and their corresponding sensitivity, specificity 
and accuracy for the EBV serologic tests are reported in Table 4.3. 
 
Figure 4.9. ROC curves for the EBV serologic tests in the classification of NPC (n = 
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Table 4.3. Performance characteristics for the EBV serologic tests in the classification 
of NPC cases (n = 120) and controls (n = 120).
 GgI/D-AE ZEBRA/IgG VCA p18/IgG 
Cutoff (PP; A630) >41.64; >0.66 >55.08; >1.18 >21.53; >0.43 
AUC (95% CI) 0.654 (0.590–0.714) 0.786 (0.729–0.836) 0.700 (0.638–0.757) 
True positive (n) 89  98  115  
True negative (n) 58  74  42  
False positive (n) 62  46  78  
False negative (n) 31  22  5  
Sensitivity (%) 74.2  81.7  95.8  
Specificity (%) 48.3  61.7  35.0  
Accuracy (%) 61.3  71.7  65.4  
Numbers in boldface denote the highest performance estimates.  
Abbreviations: EBV, Epstein-Barr virus; NPC, nasopharyngeal carcinoma; EA-D, early 
antigen-diffuse; IgG, immunoglobulin G; ZEBRA, Z-encoded broadly reactive activator; 
VCA, viral capsid antigen; PP, percentage positivity; A630, absorbance at 630 nm; AUC, 
area under the ROC curve; ROC, receiver operating characteristics; CI, confidence 
interval. 
 
In EA-D/IgG test, 89 of 120 NPC patients (74.2% sensitivity) were EA-D/IgG 
positive, whereas 58 of 120 normal subjects were EA-D/IgG negative (48.3% 
specificity). The remaining subjects could not be classified correctly. The test 
misclassified 31 of 120 NPC patients (25.8%), and 62 of 120 normal subjects (51.7%). 
In ZEBRA/IgG test, 98 of 120 NPC patients (81.7% sensitivity) were 
ZEBRA/IgG positive, while 74 of 120 normal subjects were ZEBRA/IgG negative (61.7% 
specificity). The test misclassified 22 of 120 NPC patients (18.3%), and 46 of 120 
normal subjects (38.3%). 
In VCA p18/IgG test, 115 of 120 NPC patients (95.8% sensitivity) were VCA 
p18/IgG positive, whereas 42 of 120 normal subjects were VCA p18/IgG negative (35.0% 
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specificity). The test misclassified 5 of 120 NPC patients (4.2%), and 78 of 120 normal 
subjects (65.0%). 
Further, AUC scores for the EBV serologic tests were compared using Mann-
Whitney U-statistic (Table 4.4). ZEBRA/IgG was the best performed test in 
classification of NPC (AUC differences between ZEBRA/IgG and VCA p18/IgG, and 
ZEBRA/IgG and EA-D/IgG were statistically significance). ZEBRA/IgG offered the 
highest scores of AUC (0.786), thereby yielding the best trade-off between sensitivity 
(81.7%) and specificity (61.7%). The best sensitivity (95.8%) was provided VCA 
p18/IgG, but its specificity was low (35.0%). With AUC scores between 0.7–0.9, 
ZEBRA/IgG and VCA p18/IgG had intermediate classification accuracies. Among the 
three serologic tests, EA-D/IgG was the poorest in classifying the case-control status 
(but the AUC difference between VCA p18/IgG and EA-D/IgG was not statistically 
significance). With an AUC score below 0.7, EA-D/IgG had low classification accuracy, 
and a weak association with NPC. Nevertheless,  EA-D/IgG was better than a random 
classifier. 
 
Table 4.4. Comparison of AUC scores for the EBV serologic tests.a 
EBV serologic test EA-D/IgG ZEBRA/IgG VCA p18/IgG 
EA-D/IgG — 0.132 0.046 
ZEBRA/IgG 0.00001 — 0.086 
VCA p18/IgG 0.15807 0.00231 — 
a Pairwise comparison by Mann-Whitney U-statistic implemented in StAR. Upper 
triangle: AUC differences; lower triangle: p-values. 
Abbreviations: AUC, area under the ROC curve; ROC, receiver operating 
characteristics; EBV, Epstein-Barr virus; EA-D, early antigen-diffuse; IgG, 
immunoglobulin G; ZEBRA, Z-encoded broadly reactive activator; VCA, viral capsid 
antigen; StAR; statistical analysis of ROC curves. 
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4.3.6. Assay reproducibility 
For each indirect ELISA, intra-assay precisions (n = 10) were determined from 
quadruplicate readings (well-to-well) of assay controls, whereas inter-assay precision 
was determined from average quadruplicate readings (plate-to-plate, also day-to-day 
here) of assay controls across 10 runs. Overall, the intra-assay and inter-assay precisions 
were less than or equal to 7% and 16%, respectively (Table 4.4). 
 
Table 4.5. Reproducibility of the indirect ELISAs. 
 Assay control 
 C++ C+ C− 
Intra-assay precision (CV%) (n = 10)a 
EA-D/IgG 0.4–1.7 0.9–7.0 0.5–5.8 
VCA p18/IgG 0.8–2.0 0.1–5.6 1.0–5.2 
ZEBRA/IgG 1.1–3.9 0.3–1.5 1.2–3. 6 
Inter-assay precision (CV%) (n = 10)b 
EA-D/IgG 8.1 16.0 12.9 
VCA p18/IgG 3.9 4.9 13.3 
ZEBRA/IgG 2.9 3.8 6.4 
Numbers in italic and boldface denote the lowest and highest CVs, respectively, among 
the immunoassays. 
a Determined from quadruplicate readings (well-to-well) of assay controls in the same 
runs (n=10). 
b Determined from average quadruplicate readings (plate-to-plate, also day-to-day here) 
of assay controls across 10 runs. 
Abbreviations: ELISA, enzyme-linked immunosorbent assay; C++, strong positive 
control; C+, moderately positive control; C−, negative control; CV, coefficient of 
variation; EA-D, early antigen-diffuse; IgG, immunoglobulin G; ZEBRA, Z-encoded 
broadly reactive activator; VCA, viral capsid antigen. 
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CHAPTER 5. DISCUSSION 
 
We attempted to develop in-house ELISAs to investigate the diagnostic values 
of anti-EBV IgG levels in a high-risk NPC population, i.e., Malaysian Chinese. 
Therefore, we adopted recombinant DNA approaches to express and purify the target 
proteins of EBV from E. coli. We then used the recombinant EBV proteins as antigen 
for our in-house ELISAs.  
 
5.1. PROTEIN EXPRESSION AND PURIFICATION 
5.1.1. Expression of recombinant proteins 
Because of simplicity, efficiency and cost, we chose E. coli to produce the target 
proteins. Despite recombinant proteins produced by E. coli are possibly misfolded and 
lack of post-translational modification, many ELISA studies have shown the feasibility 
of EBV proteins produced by E. coli (Dardari et al., 2001; Fachiroh et al., 2010; 
Mathew et al., 1994). 
However, when using IPTG induction, the expression of EA-D in expression 
host, BL21 Star (DE3) was low (Figure 4.3A). It was undesirable for protein 
purification because the yield and purity of the recombinant protein might be low. To 
increase the expression level of recombinant EA-D, we tried MDG non-inducing media 
to prepare the starter culture, and ZYM-5052 media to grow and to auto-induce BL21 
Star (DE3) for protein expression (Table 2.4 and 2.5) (Studier, 2005). MDG media 
prevent the leakage of T7 lac promoter of the harbored vector, while ZYM-5052 media 
provide rich nutrients that are necessary for the expression of certain recombinant 
proteins in E. coli (Studier, 2005). Under autoinduction, EA-D was expressed at a 
higher level (Figure 4.5A, left panel versus Figure 4.3A). 
Unlike LB media, certain extra nutrients supplied by ZYM-5052 media might be 
essential for the expression of EA-D in BL21 Star (DE3). However, it is not clear that 
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which nutrient(s) had stimulated the cells to express EA-D at a higher level. For future 
work, its nutrient requirement can be investigated by factorial design experiment. We 
can also explore the physiological states of E. coli samples that have different 
expression levels of the recombinant protein.  Besides, the role of MDG starter culture 
in preventing the leakage of the protein expression system should be taken into account. 
Based on the successful expression of EA-D at a higher level, auto-induction 
method was adopted to express other target proteins in BL21 Star (DE3). This approach 
allows easy handling of scale-up cultures in one-liter shake flasks because we do not 
need to monitor the cell growths in order to add IPTG timely. As expected, the 
expression levels of ZEBRA and VCA p18 using auto-induction method were 
comparable with conventional IPTG induction method (Figure 4.3B, C versus Figure 
4.5A, left panel). Taken together, our data suggested that auto-induction was the 
preferred approach for high level expression of the EBV proteins in E. coli.  Our protein 
expression strategy was therefore changed to auto-induction method. 
 
5.1.2. Purification of recombinant proteins 
To purify the His-tagged proteins of EBV, we employed membrane adsorbers, 
i.e., scale-down units that have 15 layers in each unit to carry metal-chelating groups of 
iminodiacetic acid. Membrane adsorber can be easily customized for IMAC-based 
purification because (i) its capacity can be multiplied by connecting to additional unit(s), 
(ii) it can be charged with the metal ion of choice, (iii) it is reusable by stripping and 
recharging of metal ion, and (iv) its flow rate can be controlled either by the plunger of 
syringe or peristaltic pump. 
For our application, two connecting membrane adsorbers and a syringe were 
sufficient. Cobalt ion was used to charge the purification device because it provides the 
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greatest selectivity toward His-tagged protein among the commonly used metal ions, 
such as copper, nickel and zinc ions (Sulkowski, 1989).  
For indirect ELISA, the native state of antigen is required to exhibit its 
conformational epitopes (Crowther, 2009). Hence, all recombinant proteins were 
purified under native conditions by competitive elution with imidazole for this study.  
The eluted fractions of individual proteins were pooled (Figure 4.5A, right 
panel), analyzed by SDS-PAGE, detected by Western blotting (Figure 4.5B), and 
quantified by Bradford assay. As a preliminary study, we wanted to evaluate the 
potential use of the recombinant EBV proteins produced by E. coli as antigens before 
further refinements, i.e., removing fusion tags and performing further purification. 
 
5.2. DEVELOPMENT OF INDIRECT ELISAS 
5.2.1. Selection of blocking agent 
We employed Maxisorp poly(styrene) microplate (Nunc, Denmark) as the solid 
phase for indirect ELISA because it is suitable for general use, i.e., coating of both 
hydrophobic and hydrophilic antigens. For indirect ELISA, the remaining binding 
surface after antigen immobilization must be shielded from primary and secondary 
antibodies to avoid background or noise. Because blocking agent occupies most binding 
surface of a solid phase (microplate), its ability to prevent nonspecific binding 
determines the SNR and reliability of an ELISA. 
To choose a compatible blocking agent, commonly used (BSA, NFDM and 
casein) and synthetic polymer (Ficoll, PVA and PVP) blocking agents (Huber et al., 
2009; Rodda & Yamazaki, 1994; Studentsov et al., 2002) were evaluated. BSA, NFDM 
and casein are conventional, widely used blocking agents. Their blocking effectiveness 
was therefore concerned in this experiment. On the other hand, we selected the synthetic 
polymers based on their high affinity toward poly(styrene) surfaces but lack of affinity 
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toward biomolecules (Barrett et al., 2001; Denhardt, 1966; Robinson & Williams, 2002). 
In addition, we chose low molecular weight PVA (15,000) and PVP (10,000) to achieve 
good surface coverage (Barrett et al., 2001), meanwhile avoiding steric hindrance in the 
subsequent immunodetection steps. With different building blocks from proteins—
hence no antigenic determinant—these synthetic polymers should not interfere with the 
immunoassay. 
The fundamental difference between the assay of this experiment with a normal 
run of indirect ELISA is that empty microplates were directly blocked with blocking 
buffer instead of coated with antigen. Therefore, the detection of sample background 
was solely based on nonspecific binding of materials from a diluted plasma sample to an 
immobilized layer of blocking agent.  
In this experiment, full assay controls for each microplate comprised of SC1, 
SC2, CC, C++, C+ and C− (Table 2.8). The positivity for C++, C+ and C− assay 
controls was determined by checkerboard titrations (Figure 4.8). 
From the raw absorbance values, we noticed that the variations of sample 
backgrounds were attributed to the blocking buffers used (Table 4.2). It should be 
emphasized that a blocking agent is suitable for ELISA serology only if sample 
backgrounds from both cases and controls are homogeneous (close to each other) and 
sufficiently low to avoid false positive signals. However, high backgrounds were 
observed when using NFDM as blocking agent. Unlike commonly used blocking agents, 
Ficoll (in both 1×PBS and coating buffers) and PVA (in coating buffer) provided 
relatively low and narrow range of sample backgrounds. 
 
5.2.2. Grid experiments 
The blocking ability of PVA was further investigated because it is clinically 
proven to be non-immunogenic (Nair, 1998), and 30-fold cheaper than Ficoll (Table 
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5.1). Because the assembly of PVA chains on a solid phase may be influenced by 
polymer concentration, composition of kosmotrope(s), temperature (Barrett et al., 2001; 
Kozlov & McCarthy, 2004) and pH, we optimized the blocking steps in grid 
experiments (Figure 2.1). 
 
Table 5.1. Price of blocking agents by November 2011. 
Blocking agent Company Product code Quantity Unit price (MYR) 
Cost per platea 
(MYR) 
BSA Sigma A6003 100 g 4,525.22  18.10
NFDM KPL 50-82-01 200 ml 683.00  1.71
Casein Merck 218682 500 g 624.00  0.50
Ficoll Sigma F4375 500 g 4,715.22  3.77
PVA Merck 843865 1 kg 323.00  0.13
PVP Sigma PVP10 1 kg 937.46  0.37
a A total of 30 microplates are needed in the present study (three assays in 10 routine 
runs). 
Abbreviations: MYR, Malaysian ringgits; BSA, bovine serum albumin; NFDM, nonfat 
dry milk; PVA, poly(vinyl alcohol); PVP, poly(vinyl pyrrolidone). 
 
From the grid experiments, 4% (w/v) PVA provided the most effective blocking, 
viz., the lowest backgrounds across different dilutions of plasma pools from both NPC 
(n = 4) and normal (n = 4) subjects (Figure 4.6). For polymer concentrations below 2% 
(w/v), backgrounds that correspond to PVA layers formed in 1×PBS were relatively 
lower than those formed in coating buffer. It may be due to higher concentrations of 
kosmotropes (especially NaCl) in 1×PBS, which could promote the adsorption of PVA 
(Kozlov & McCarthy, 2004). The kosmotropes could stabilize water structure, and 
exhibit “salting out” effect by strengthening the hydrophobic interactions between PVA 
and poly(styrene) surface. Therefore, available surface on the solid phase could be 
occupied more readily at lower polymer concentrations. This mechanism clarifies why 
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Huber et al. (2009) demonstrated the effective blocking of 1% (w/v) PVA (no data for 
other concentrations) in 1×PBS rather than coating buffer. By contrast, the effects of 
kosmotropes were not obvious above 2% (w/v) PVA (Figure 4.6). Moreover, Table 4.2 
shows that the sample backgrounds that correspond to all 4% (w/v) synthetic polymers 
in coating buffer are relatively lower than those in 1×PBS. 
In order to select a diluent for 4% (w/v) PVA, we included additional 12 NPC 
samples to study their sample backgrounds and SNRs. For sample backgrounds, our 
results (Figure 4.7) agree well with the observation from Table 4.2, suggesting that the 
assembly of PVA chains at 4% (w/v) and high pH (coating buffer, pH 9.6) is more 
resistant to nonspecific binding. However, the underlying mechanism is still not clear to 
us. Overnight incubation was not further examined because a stable PVA layer could be 
formed in 2 h at room temperature (Barrett et al., 2001). 
 
5.2.3. Comparison of SNRs 
The commonly used blocking agents are able to occupy available active sites of 
a solid phase well (no anomalous background for CC, i.e., A630 values lower than 0.20), 
but the immunogenicity of these animal proteins in human (Dise & Brunell, 1987) may 
adversely affect the SNRs of serological assays. To demonstrate this point, we 
compared the SNRs for this 24 NPC samples in assays using NFDM and PVA as 
blocking agents. The SNR for individual sample was estimated as the ratio of 
corresponding A630 values from assays with to without immobilized antigen (ZEBRA). 
The raw absorbance values of signals and noises (sample backgrounds) that 
correspond to NFDM were indistinguishable (Wilcoxon signed rank test: z = 1.97, p = 
0.049, r = 0.40) (Figure 4.7). By contrast, a clear-cut between signals and noises were 
shown when PVA was used as blocking agent (Wilcoxon signed rank test: z = 4.29, p = 
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1.19×10−7, r = 0.87). Here, the SNRs that correspond to blocking using 4% (w/v) PVA 
in coating buffer were 4.26-fold, on average, higher than those blocking using NFDM. 
With equivalent signal intensities but relatively lower sample backgrounds 
(Figure 4.7), the SNRs that correspond to blocking using 4% (w/v) PVA in coating 
buffer were 1.25-fold, on average, higher than those blocking using 4% (w/v) PVA in 
1×PBS. These results again suggested that 4% (w/v) PVA in coating buffer is optimum. 
Thus, the optimum blocking step was used in the subsequent experiments. 
Besides blocking agent, other possibilities for high sample backgrounds are 
incomplete washing and poor quality of conjugate. From our observations, however, 
both possibilities can be ruled out because: (i) compared with NFDM, sample 
backgrounds that correspond to other blocking agents were much lower. Moreover, 4% 
(w/v) synthetic polymers that prepared in coating buffer were more effective than those 
prepared in 1×PBS although all microplates underwent the same wash steps by an 
automated washer. Both observations cannot be explained if the former possibility 
(incomplete washing) is true. (ii) The latter possibility (poor quality of conjugate) may 
not valid because wells for CC did not produce anomalous background (A630 values 
lower than 0.20).  
 
5.2.4. Checkerboard titrations 
Using C++, C+ and C− assay controls, checkerboard titrations were performed 
to titrate the key reagents for indirect ELISAs (antigen, plasma, and conjugate) (see 
Section 3.3.4). With optimized reagents, decreasing A630 values were observed with 
increasing dilutions of the assay controls until their endpoints (Figure 4.8). Four-
parameter logistic function was used to fit the endpoint titration curves for C++ and C+. 
The R2 of the fitted curves were above 0.99, suggesting that backgrounds across the 
titrations are minimal (if the blocking agent contributes high backgrounds, endpoint 
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titrations of C++ and C+ could not be obtained, therefore R2 values of the non-sigmoidal 
titration curves will be lower than 0.99). On the other hand, the data also suggested that 
the PVA blocking layer does not interfere with the signal formations upon the titrations 
of reagents. 
 
5.2.5. Serologic tests 
With optimized reagents, ELISA serology was performed on 120 case-control 
pairs. Because age, gender and ethnicity are confounding factors on NPC risk, only age- 
and gender-matched, case-control pairs of Malaysian Chinese were assayed (see Section 
3.1.2 and 4.1). 
The ELISA results for NPC cases and controls were expressed as PP values (see 
equation (1) in Section 4.2.5). NPC cases were labeled as true positive while normal 
subjects were labeled as true negative. On this basis, ELISA results from EA-D/IgG, 
ZEBRA/IgG and VCA p18/IgG were used to classify NPC cases and controls. The 
performance for each serologic test was characterized by ROC (Figure 4.9). 
Table 4.3 summarizes the cutoff value, sensitivity, specificity and AUC for each 
serologic test. Certainly, a good serologic test has high sensitivity and specificity. In real 
world situations, however, ROC curves for serologic tests often display the trade-off 
between sensitivity and specificity at different cutoff values, as shown in Figure 4.8. 
From the ROC curves, ZEBRA/IgG is the best performed test, followed by VCA 
p18/IgG and EA-D/IgG, because (i) the ROC curve for ZEBRA/IgG lies nearer to upper 
left corner of the ROC space, scoring the highest AUC (0.786), and (ii) the AUC 
differences between ZEBRA/IgG and the other two EBV serologic tests were 
statistically significance (Table 4.4). Therefore, ZEBRA/IgG had the highest 
sensitivities and specificities at most of the cutoff values.  
CHAPTER 5. DISCUSSION 
63 
 
Despite no consensus in experimental setup and data analysis, ZEBRA/IgG by 
ELISA had been suggested as a potential test for Malaysian NPC patients by a previous 
study (Mathew et al., 1994).  Mathew et al. (1994) developed their in-house ELISA and 
IFA for ZEBRA/IgG (using recombinant ZEBRA protein produced by E. coli) and 
VCA/IgA, respectively. From 100 NPC patients with VCA/IgA (IFA) positive, they 
found that 75 were ZEBRA/IgG positive (75%). Although the VCA/IgA (IFA) 
positivity of our NPC cases were unknown, the sensitivity (81.7%) of our assay was 
higher. On the other hand, out of 83 normal subjects, they found that three were 
ZEBRA/IgG positive (3.6%), indicating a specificity of 96.4%, which was much higher 
than the specificity (61.7%) of our assay. However, this difference might be due to 
spectrum bias because their normal subjects (n = 83) did not match with NPC patients 
(n = 100). 
Besides ZEBRA/IgG, the trade-offs between sensitivity and specificity for both 
VCA p18/IgG and EA-D/IgG were not satisfactory.  
A few limitations in the present study should be noted. (i) The EBV proteins are 
based on a single EBV strain B95-8 (GenBank V01555) originated from a North 
American case of infectious mononucleosis (Miller & Lipman, 1973), which may not be 
as effective as the EBV proteins based on GD1 originated from a Guangdong Chinese 
case of nasopharyngeal carcinoma (Zeng et al., 2005). We have done multiple sequence 
alignments of EA-D, ZEBRA and VCA p18 for the only available EBV strains, B95-8, 
AG876 (originated from a West African case of Burkitt's lymphoma (Pizzo et al., 1978)) 
and GD1 using Clustal Omega (Sievers et al., 2011) at UniProt (http://www.uniprot.org) 
(see Appendix D). We found several variations between the amino acid sequences, 
suggesting comparisons of immunogenicity between the EBV proteins of different 
strains are necessary for the development of the ELISAs. (ii) During the development of 
the ELISAs, we chose PVA instead of Ficoll as blocking agent, which was based on 
CHAPTER 5. DISCUSSION 
64 
 
cost considerations (Table 5.1) and some published data showing the effective blocking 
of PVA (Rodda & Yamazaki, 1994; Studentsov et al., 2002; Huber et al., 2009). To the 
best of our knowledge, however, only Huber et al. (2009) reported Ficoll as an effective 
blocking agent. The results in Table 4.2 suggested that Ficoll contributed lower 
backgrounds with tighter range than PVA, ELISAs using Ficoll as blocking agent may 
be more reliable than that of PVA. (iii) Our NPC samples were obtained from prevalent 
cases, which were in remission. After cancer therapy, their anti-EBV antibody levels 
(IgG against EA-D, and synthetic peptides of EBNA-1, and gp78; IgA against EA-D, 
gp125, and synthetic peptides of EBNA-1, gp78, VCA p18) might be altered (Gu et al., 
2009b). Therefore, the overall diagnostic performances of ZEBRA/IgG, VCA p18/IgG, 
and EA-D/IgG for detection of NPC in other geographical areas (Table 5.1) are better 
than our results. (iv) In addition, the ELISA results may be bias, representing only a 
portion of the prevalent NPC cases who survive longer (long enough to attend the 
follow-up appointments) because we might not be able to collect blood samples from 
NPC patients who die quickly. (v) Because of the discrepancies in EBV infection status 
and health condition, anti-EBV IgG levels in cases and controls may have temporal 
variations. (vi) Because of limited number of study subjects, we did not randomly split 
the study subjects into two sets, in which one set is for training (to obtain cutoff values 
of the EBV serologic tests by ROC analysis) and another independent set is for testing 
(to evaluate the sensitivities and specificities of the EBV serologic tests). Therefore, the 
cutoff values may not robust and the diagnostic performances of the serologic tests may 
not reproducible. (vii) We did not assess the EBV serologic tests with positive 
predictive values and negative predictive values because these parameters depend on the 
prevalence of NPC in Malaysian Chinese population that is still undetermined.  
For future work, the serological assays should be repeated using EBV proteins 
with higher purity and without fusion tags in order to improve the diagnostic 
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performances of the in-house ELISAs. Also, the diagnostic performances of ELISA 
using PVA as blocking agent should be compared with that of Ficoll. More samples are 
required to obtain EBV serologic data in full spectrum of NPC subtypes and staging. In 
addition, all samples should be screened for long term, including the use of other 
serologic markers such as EBNA-1/IgG, and IgA-based indirect ELISA. Notably, the 
prognostic value of EBNA-1/IgA by ELISA was recently found to be higher than the 
most popular EBV marker for NPC, VCA/IgA by IFA (Yu et al., 2011). Besides, the 
performances of our in-house assays should be compared with commercial kits. 
 Table 5.2. Diagnostic performances of ELISAs (EA-D/IgG, VCA/IgG, and ZEBRA/IgG) for detection of NPC in different geographical areas 
(selected communications since 2000). 
Author and year Area (population) Incident cases and controls ELISA appr  )%( yticificeps dna ytivitisneS hcao
Abdulamir et 
al., 2010 
Iraq and Jordan 
(native Middle 
Eastern people of 
Arabic ethnicity) 
42 NPC cases; 
66 carcinoma of larynx; 
14 hypopharyngeal carcinoma; 
300 healthy controls; 
cases were matched with 
controls by age and gender. 
VCA/IgG (in-house ELISA using VCA 
purchased from Wellcome, England) 
76.2; 86 
Dardari et al., 
2008 
Rabat and 
Casablanca, 
Morocco 
255 NPC cases: 25 children 
(≤15 years), 59 young (16–30 
years), 171 adults (>30 years); 
266 healthy controls; 
cases were matched with 
controls by age and gender. 
 nerdlihC  ASILE esuoh-nI
(≤15 years) 
Young 
(16–30 years) 
Adults 
(>30 years) 
ZEBRA/IgG (using recombinant ZEBRA 
protein produced by E. coli) 
100; 100 93; 100 96; 96 
Zp125/IgG (using synthetic peptide) 80; 88 69; 94 73; 83 
Zp130/IgG (using synthetic peptide) 67; 100 41; 100 48; 100 
Gu et al., 2008b Guangzhou, 
China 
135 NPC cases; 
130 heathy controls. 
EA-D/IgG (ELISA kit purchased from IBL, 
Germany, using recombinant EA-D protein 
produced by E. coli) 
85.2; 82.3 
Paramita et al., 
2007 
Yogyakarta, 
Indonesia 
151 NPC cases; 
259 healthy controls. 
EA-D/IgG (in-house ELISA using EA-D 
extract from HH514.c16 cell, which was 
induced by 3mM sodium butyrate, 20 ng/ml 
12-O-tetradecanoylphorbol-13-acetate and 0.5 
mM phosphonoacetic acid) 
90.4; 95.5 
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Table 5.2, continued. 
Author and year Area (population) Incident cases and controls ELISA appr  )%( yticificeps dna ytivitisneS hcao
Tedeschi et al., 
2007 
Italy (native and 
resident of Italy) 
77 NPC cases; 
54 healthy controls; 
cases were matched with 
controls by age and gender. 
ZEBRA/IgG (in-house ELISA using synthetic 
peptide) 
61; 94.4 
Chan et al., 
2003 
Hong Kong 218 suspected NPC subjects: 
cases (51 developed NPC, 4 
developed lymphoepithelioma 
like cancer of the lung); 
controls (23 developed other 
cancer, 140 did not have 
tumor). 
ZEBRA/IgG (ELISA kit purchased from 
Sinoclone, Hong Kong, using a recombinant 
polypeptide produced by E. coli) 
74.5, 82.8 
Cheng W.-M. et 
al., 2002 
Hong Kong and 
Zhongshan, 
China (residents 
of Pearl River 
estuary) 
121 NPC cases; 
332 healthy controls. 
ZEBRA/IgG (ELISA kit purchased from 
Sinoclone, Hong Kong, using a recombinant 
polypeptide produced by E. coli) 
79; 80 
Abbreviations: ELISA, enzyme-linked immunosorbent assay; EA-D, early antigen-diffuse; IgG, immunoglobulin G; ZEBRA, Z-encoded 
broadly reactive activator; VCA, viral capsid antigen; NPC, nasopharyngeal carcinoma.
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5.2.6. Assay reproducibility 
In our routine ELISA study, all microplates were incorporated with full assay 
controls, namely SC1, CC, blank, C++, C+ and C− in quadruplicates (see Section 3.3.6). 
The assay reproducibility was determined from the measurements of C++, C+ and C−. 
The intra- and inter-assay precisions obtained were less than 7% and 16%, respectively 
(Table 4.4), suggesting that the assay reproducibility is acceptable. 
The measurements of SC1, CC and blank were consistently lower than 0.05, 
0.15 and 0.20, respectively. For SC1, the low readings suggested that the substrate 
system is in good condition. For CC and blank, the low backgrounds suggested the lack 
of nonspecific binding of conjugate to the solid phase upon PVA blocking, and upon 
antigen coating and PVA blocking, respectively. Taken together, these observations also 
suggested that PVA blocking agent may consistently form an inert layer, which favors 
the assembly of specific immune complex. 
For future work, we would like to examine: (i) the effects of interfering 
substances in plasma or serum, (ii) the cross-reactivity, (iii) the limit of detection and 
limit of quantification, and (iv) the linearity of the assays. 
 
5.2.7. Suggested use of serologic test 
Because there are high-risk and low-risk populations for NPC (Figure 2.1), a 
good population screening strategy would be adopting a highly sensitive test and a 
highly specific test to the high-risk and low-risk populations, respectively. Using the 
NPC incidence rate of 1 per 100,000 as a benchmark, individuals above age 25 from the 
high-risk populations should participate in the screening program adopting a highly 
sensitive test in order to minimize the number of those with disease undetected. On the 
other hand, individuals above age 45 from the low-risk populations should participate in 
the screening program adopting a highly specific test in order to minimize the number 
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of those without disease subjected for further monitoring. For Malaysian Chinese, one 
of the high-risk populations for NPC (Figure 2.2), ZEBRA/IgG and VCA p18/IgG tests 
with higher sensitivities may be better choices than EA-D/IgG test (Table 4.3).  
However, the sensitivity and specificity of a serologic test should not be used to 
estimate the probability of a disease in individuals because they are merely the 
quantitative estimates of the diagnostic ability of the test (Deeks, 2004). 
By contrast, likelihood ratio (LR), which derived from the sensitivity and 
specificity of a test, is more clinically useful than other statistics in calculating the 
probability of a disease (Deeks, 2004).  
Positive LR, LR+ = sensitivity / (1 − specificity)                                                             (6) 
Negative LR, LR− = (1 – sensitivity) / specificity                                                           (7) 
In the context of evidence-based laboratory medicine, LR greater than 10 or less 
than 0.1 has a strong impact on clinical decision (Deeks, 2004). Based on Bayes' 
theorem and above statistics, here we illustrate a fictional case study to suggest the 
practical application of our EBV serologic test. 
A 45-year-old Malaysian Chinese male and his first-degree family members 
participated in a serologic screening program that organized by our research group. We 
assume that the pretest probability for the Chinese male to have NPC is 0.6% (see 
Section 4.1). To the best of our knowledge, the population-based data for family history 
of NPC in Malaysian Chinese is not publicly available. 
His ZEBRA/IgG test had a PP value of 92.70. LR1+ at this level is 0.367 / (1 – 
0.967) = 11.12 (see Appendix B). This means that he was about 11 times more likely to 
have NPC than a person with the same PP value without NPC. He was therefore referred
to an otolaryngologist for clinical examinations. Endoscopy and MRI were done. To the 
best of our knowledge, the diagnostic performances of Endoscopy and MRI for 
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Malaysian Chinese population are not publicly available. Therefore, we assume that the 
data from King et al. (2011) are applicable to Malaysian Chinese population.  
Situation A: what about if he has positive results in both endoscopy and MRI 
examinations? For endoscopy, sensitivity and specificity are 90% and 93%, respectively 
(King et al., 2011); LR2+ is 0.90 / (1 − 0.93) = 12.86. For MRI, sensitivity and 
specificity are 100% and 93%, respectively (King et al., 2011); LR3+ is 1 / (1 – 0.93) = 
14.29. 
Because this is a sequential testing, LR should be calculated as LR1+ × LR2+ × 
LR3+ = 11.12 × 12.86 × 14.29 = 2043.52. One can use Fagan's nomogram to project a 
pretest probability to a post-test probability (probability of a subject to have a disease 
after a test) via LR (Deeks, 2004). However, hand-charting is not suitable here because 
the LR is beyond the scale of a standard Fagan's nomogram (see gray dashed line in 
Figure 5.1). Therefore, we calculate his post-test probability by the following equations 
(Deeks, 2004): 
Let Pretest probability = p1, Pretest odds = p1 / (1 − p1)                                                  (8) 
Post-test odds, o2 = Pretest odds × LR                                                                             (9) 
Post-test probability = o2 / (1 + o2)                                                                                 (10)                  
Pretest odds = 0.006 / (1 − 0.006) = 0.006. Post-test odds = 0.006 × 2043.52 = 
12.261. Post-test probability = 12.261 / (1 + 12.261) = 0.925. Here, the probability of 
this man to have NPC increases from 0.6% to 92.5%, suggesting that endoscopic biopsy 
is needed for definitive histological diagnosis. 
Situation B: what about if he has a negative result in endoscopy inspection, but a 
positive result in MRI examination? This may happen when MRI reveals the tumor site 
that missed during endoscopic inspection. For endoscopy, LR2− is (1 – 0.9) / 0.93 = 0.11. 
For MRI, LR3+ is the same, 14.29. LR can be calculated as LR1+ × LR2− × LR3+ = 11.12 
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× 0.11 × 14.29 = 17.48. Post-test probability can be obtained from Fagan's nomogram 
(see gray solid line in Figure 5.1), or calculation in the following paragraph. 
Post-test odds = 0.006 × 17.48 = 0.105. Post-test probability is 0.105 / (1 + 
0.105) = 0.095. The probability of this man to have NPC increases from 0.6% to 9.5%, 
suggesting that endoscopic biopsy is needed for definitive histological diagnosis. If he is 
having NPC but do not undergo the serologic test at first, he may be ruled out from 
having NPC, because of no further clinical examination when he is negative in 
endoscopic inspection. 
In both possible outcomes, the result of EBV serologic test can exert a strong 
influence on clinical management. However, we suggest validating such approach on an 
independent set of samples before applying it to patient management.  
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Figure 5.1. Fagan's nomograms show the leverages of pretest into post-test probabilities 
by LRs in a fictional NPC case study (see gray lines). Given that his has a PP value of 
92.70 in ZEBRA/IgG test (LR1+ = 11.12), in situation A, positive in both endoscopy 
(LR2+ = 12.86) and MRI (LR3+ = 14.29) examinations could yield a post-test probability 
of 92.5% (see dashed line); in situation B, negative in endoscopic inspection (LR2− = 
0.11) but positive in MRI examination (LR3+ = 14.29) could yield a post-test probability 
of 9.5% (see solid line). 
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CHAPTER 6. CONCLUSION 
 
 NPC is a prevalent cancer in Malaysian Chinese, especially in male population. 
The ratio of enrolled Chinese male to female patients was 3:1. Also, we noted the 
familial clustering of NPC, in which 14.19% Chinese patients were familial NPC cases. 
In our pilot survey of prevalence, three of 334 normal subjects of Chinese descent had a 
first-degree relative (n = 2) or spouse (n = 1) affected by NPC. Notably, these three 
NPC cases are males. By contrast, 324 normal subjects of other ethnicity did not have 
family history of NPC. 
 Using recombinant EBV proteins (EA-D, ZEBRA, and VCA p18) purified from 
E. coli, we developed indirect ELISAs (EA-D/IgG, ZEBRA/IgG, and VCA p18/IgG) 
for detection of NPC. 
Among the 120 age- and gender-matched case-control pairs (all Chinese), NPC 
patients showed elevated levels of anti-EBV antibodies. Our study also demonstrated 
that IgG against ZEBRA is a better clinical indicator for NPC (81.7% sensitivity, 61.7% 
specificity) compared with IgG against EA-D (74.2% sensitivity, 48.3% specificity) and 
VCA p18 (95.8% sensitivity, 35.0% specificity). The diagnostic accuracies of in-house 
ELISAs must be improved before selective screening of NPC in high-risk population in 
Malaysia can be proposed. 
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Appendix A. Counting of study subjects according to EA-D/IgG positivity (cutoff 
values), Youden's index and coordinates of the ROC curve.a 
Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
≥11.80 120 120 1.000 0.000 0.000 1.000 
120 119 1.000 0.008 0.008 0.992 
120 118 1.000 0.017 0.017 0.983 
120 117 1.000 0.025 0.025 0.975 
120 116 1.000 0.033 0.033 0.967 
119 116 0.992 0.033 0.025 0.967 
119 115 0.992 0.042 0.033 0.958 
119 114 0.992 0.050 0.042 0.950 
119 113 0.992 0.058 0.050 0.942 
119 112 0.992 0.067 0.058 0.933 
119 111 0.992 0.075 0.067 0.925 
119 110 0.992 0.083 0.075 0.917 
119 109 0.992 0.092 0.083 0.908 
118 109 0.983 0.092 0.075 0.908 
118 108 0.983 0.100 0.083 0.900 
118 107 0.983 0.108 0.092 0.892 
117 107 0.975 0.108 0.083 0.892 
116 107 0.967 0.108 0.075 0.892 
116 106 0.967 0.117 0.083 0.883 
115 106 0.958 0.117 0.075 0.883 
115 105 0.958 0.125 0.083 0.875 
115 104 0.958 0.133 0.092 0.867 
115 103 0.958 0.142 0.100 0.858 
115 102 0.958 0.150 0.108 0.850 
114 102 0.950 0.150 0.100 0.850 
113 102 0.942 0.150 0.092 0.850 
113 101 0.942 0.158 0.100 0.842 
113 100 0.942 0.167 0.108 0.833 
113 99 0.942 0.175 0.117 0.825 
112 99 0.933 0.175 0.108 0.825 
112 98 0.933 0.183 0.117 0.817 
112 97 0.933 0.192 0.125 0.808 
112 96 0.933 0.200 0.133 0.800 
 112 95 0.933 0.208 0.142 0.792 
>14.35 
>14.81 
>14.94 
>16.48 
>16.94 
>17.24 
>19.10 
>20.25 
>20.45 
>20.61 
>20.83 
>21.00 
>21.31 
>21.50 
>22.94 
>23.84 
>24.48 
>24.49 
>24.94 
>25.18 
>25.53 
>25.65 
>25.70 
>25.83 
>26.06 
>26.16 
>26.52 
>27.12 
>27.75 
>28.33 
>28.42 
>29.15
>11.80
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Appendix A, continued. 
Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
111 95 0.925 0.208 0.133 0.792 
110 95 0.917 0.208 0.125 0.792 
110 94 0.917 0.217 0.133 0.783 
109 94 0.908 0.217 0.125 0.783 
109 93 0.908 0.225 0.133 0.775 
108 93 0.900 0.225 0.125 0.775 
108 92 0.900 0.233 0.133 0.767 
108 91 0.900 0.242 0.142 0.758 
108 90 0.900 0.250 0.150 0.750 
108 89 0.900 0.258 0.158 0.742 
108 88 0.900 0.267 0.167 0.733 
107 88 0.892 0.267 0.158 0.733 
106 88 0.883 0.267 0.150 0.733 
106 87 0.883 0.275 0.158 0.725 
106 86 0.883 0.283 0.167 0.717 
105 86 0.875 0.283 0.158 0.717 
104 86 0.867 0.283 0.150 0.717 
104 85 0.867 0.292 0.158 0.708 
104 84 0.867 0.300 0.167 0.700 
104 83 0.867 0.308 0.175 0.692 
104 82 0.867 0.317 0.183 0.683 
104 81 0.867 0.325 0.192 0.675 
103 81 0.858 0.325 0.183 0.675 
102 81 0.850 0.325 0.175 0.675 
102 80 0.850 0.333 0.183 0.667 
102 79 0.850 0.342 0.192 0.658 
101 79 0.842 0.342 0.183 0.658 
101 78 0.842 0.350 0.192 0.650 
100 78 0.833 0.350 0.183 0.650 
100 77 0.833 0.358 0.192 0.642 
99 77 0.825 0.358 0.183 0.642 
98 77 0.817 0.358 0.175 0.642 
97 77 0.808 0.358 0.167 0.642 
97 76 0.808 0.367 0.175 0.633 
 96 76 0.800 0.367 0.167 0.633 
>29.41 
>29.48 
>30.04 
>30.39 
>30.74 
>30.75 
>30.92 
>31.21 
>31.38 
>31.53 
>31.65 
>31.67 
>31.88 
>31.93 
>32.39 
>32.48 
>32.82 
>32.91 
>33.19 
>33.42 
>33.60 
>33.84 
>34.17 
>34.27 
>34.33 
>34.38 
>34.52 
>34.69 
>34.73 
>35.11 
>35.34 
>35.40 
>35.63 
>36.12
>29.34
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Appendix A, continued. 
Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
96 75 0.800 0.375 0.175 0.625 
96 74 0.800 0.383 0.183 0.617 
96 73 0.800 0.392 0.192 0.608 
95 73 0.792 0.392 0.183 0.608 
95 72 0.792 0.400 0.192 0.600 
94 72 0.783 0.400 0.183 0.600 
93 72 0.775 0.400 0.175 0.600 
92 72 0.767 0.400 0.167 0.600 
92 71 0.767 0.408 0.175 0.592 
91 71 0.758 0.408 0.167 0.592 
91 70 0.758 0.417 0.175 0.583 
91 69 0.758 0.425 0.183 0.575 
91 68 0.758 0.433 0.192 0.567 
91 67 0.758 0.442 0.200 0.558 
90 67 0.750 0.442 0.192 0.558 
90 66 0.750 0.450 0.200 0.550 
89 66 0.742 0.450 0.192 0.550 
89 65 0.742 0.458 0.200 0.542 
89 64 0.742 0.467 0.208 0.533 
89 63 0.742 0.475 0.217 0.525 
89 62 0.742 0.483 0.225 0.517 
88 62 0.733 0.483 0.217 0.517 
87 62 0.725 0.483 0.208 0.517 
86 62 0.717 0.483 0.200 0.517 
85 62 0.708 0.483 0.192 0.517 
84 62 0.700 0.483 0.183 0.517 
83 62 0.692 0.483 0.175 0.517 
82 62 0.683 0.483 0.167 0.517 
82 61 0.683 0.492 0.175 0.508 
81 61 0.675 0.492 0.167 0.508 
80 61 0.667 0.492 0.158 0.508 
80 60 0.667 0.500 0.167 0.500 
79 60 0.658 0.500 0.158 0.500 
79 59 0.658 0.508 0.167 0.492 
>36.13
79 58 0.658 0.517 0.175 0.483 
>36.42 
>36.44 
>36.54 
>36.63 
>36.67 
>36.88 
>37.01 
>37.16 
>37.51 
>38.61 
>38.81 
>39.01 
>40.05 
>40.52 
>40.69 
>41.05 
>41.14 
>41.18 
>41.33 
>41.64 
>41.86 
>41.98 
>42.06 
>42.22 
>42.51 
>42.67 
>42.76 
>42.94 
>43.64 
>43.64 
>43.80 
>43.91 
>44.47 
>45.06 
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Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
 79 57 0.658 0.525 0.183 0.475 
 79 56 0.658 0.533 0.192 0.467 
 78 56 0.650 0.533 0.183 0.467 
 78 55 0.650 0.542 0.192 0.458 
 77 55 0.642 0.542 0.183 0.458 
 77 54 0.642 0.550 0.192 0.450 
 76 54 0.633 0.550 0.183 0.450 
 76 53 0.633 0.558 0.192 0.442 
 76 52 0.633 0.567 0.200 0.433 
 75 52 0.625 0.567 0.192 0.433 
 75 51 0.625 0.575 0.200 0.425 
 75 50 0.625 0.583 0.208 0.417 
 74 50 0.617 0.583 0.200 0.417 
 74 49 0.617 0.592 0.208 0.408 
 74 48 0.617 0.600 0.217 0.400 
 73 48 0.608 0.600 0.208 0.400 
 72 48 0.600 0.600 0.200 0.400 
 71 48 0.592 0.600 0.192 0.400 
 71 47 0.592 0.608 0.200 0.392 
 70 47 0.583 0.608 0.192 0.392 
 69 47 0.575 0.608 0.183 0.392 
 68 47 0.567 0.608 0.175 0.392 
 68 46 0.567 0.617 0.183 0.383 
 67 46 0.558 0.617 0.175 0.383 
 67 45 0.558 0.625 0.183 0.375 
 67 44 0.558 0.633 0.192 0.367 
 66 44 0.550 0.633 0.183 0.367 
 65 44 0.542 0.633 0.175 0.367 
 65 43 0.542 0.642 0.183 0.358 
 64 43 0.533 0.642 0.175 0.358 
 63 43 0.525 0.642 0.167 0.358 
 62 43 0.517 0.642 0.158 0.358 
 62 42 0.517 0.650 0.167 0.350 
 61 42 0.508 0.650 0.158 0.350 
>45.35
 60 42 0.500 0.650 0.150 0.350 
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>45.44
>45.82
>45.86
>45.90
>45.91
>46.04
>46.52
>47.46
>47.49
>48.28
>48.46
>48.70
>48.74
>48.78
>48.87
>49.22
>49.27
>49.39
>49.98
>50.06
>50.12
>50.21
>50.52
>50.68
>50.88
>51.58
>51.95
>51.98
>52.11
>52.19
>52.32
>52.40
>52.53
>52.97
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Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
60 41 0.500 0.658 0.158 0.342 
60 40 0.500 0.667 0.167 0.333 
60 39 0.500 0.675 0.175 0.325 
60 38 0.500 0.683 0.183 0.317 
59 38 0.492 0.683 0.175 0.317 
59 37 0.492 0.692 0.183 0.308 
59 36 0.492 0.700 0.192 0.300 
58 36 0.483 0.700 0.183 0.300 
57 36 0.475 0.700 0.175 0.300 
56 36 0.467 0.700 0.167 0.300 
55 36 0.458 0.700 0.158 0.300 
55 35 0.458 0.708 0.167 0.292 
54 35 0.450 0.708 0.158 0.292 
54 34 0.450 0.717 0.167 0.283 
54 33 0.450 0.725 0.175 0.275 
53 33 0.442 0.725 0.167 0.275 
53 32 0.442 0.733 0.175 0.267 
53 31 0.442 0.742 0.183 0.258 
53 30 0.442 0.750 0.192 0.250 
52 30 0.433 0.750 0.183 0.250 
52 29 0.433 0.758 0.192 0.242 
51 29 0.425 0.758 0.183 0.242 
51 28 0.425 0.767 0.192 0.233 
50 28 0.417 0.767 0.183 0.233 
50 27 0.417 0.775 0.192 0.225 
50 26 0.417 0.783 0.200 0.217 
49 26 0.408 0.783 0.192 0.217 
48 26 0.400 0.783 0.183 0.217 
47 26 0.392 0.783 0.175 0.217 
46 26 0.383 0.783 0.167 0.217 
46 25 0.383 0.792 0.175 0.208 
45 25 0.375 0.792 0.167 0.208 
45 24 0.375 0.800 0.175 0.200 
45 23 0.375 0.808 0.183 0.192 
>53.07
 44 23 0.367 0.808 0.175 0.192 
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>53.26 
>53.61 
>53.93 
>53.99 
>54.60 
>54.62 
>54.76 
>55.03 
>55.14 
>55.22 
>55.69 
>56.12 
>56.60 
>56.80 
>56.96 
>57.21 
>57.68 
>58.16 
>58.68 
>58.94 
>59.73 
>59.86 
>60.19 
>60.21 
>60.76 
>61.41 
>62.14 
>62.47 
>62.62 
>63.13 
>63.29 
>63.42 
>63.56 
>63.63
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Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
43 23 0.358 0.808 0.167 0.192 
42 23 0.350 0.808 0.158 0.192 
41 23 0.342 0.808 0.150 0.192 
41 22 0.342 0.817 0.158 0.183 
40 22 0.333 0.817 0.150 0.183 
39 22 0.325 0.817 0.142 0.183 
39 21 0.325 0.825 0.150 0.175 
39 20 0.325 0.833 0.158 0.167 
39 19 0.325 0.842 0.167 0.158 
39 18 0.325 0.850 0.175 0.150 
39 17 0.325 0.858 0.183 0.142 
38 17 0.317 0.858 0.175 0.142 
37 17 0.308 0.858 0.167 0.142 
37 16 0.308 0.867 0.175 0.133 
37 15 0.308 0.875 0.183 0.125 
37 14 0.308 0.883 0.192 0.117 
36 14 0.300 0.883 0.183 0.117 
36 13 0.300 0.892 0.192 0.108 
35 13 0.292 0.892 0.183 0.108 
34 13 0.283 0.892 0.175 0.108 
33 13 0.275 0.892 0.167 0.108 
32 13 0.267 0.892 0.158 0.108 
32 12 0.267 0.900 0.167 0.100 
32 11 0.267 0.908 0.175 0.092 
31 11 0.258 0.908 0.167 0.092 
31 10 0.258 0.917 0.175 0.083 
30 10 0.250 0.917 0.167 0.083 
29 10 0.242 0.917 0.158 0.083 
29 9 0.242 0.925 0.167 0.075 
28 9 0.233 0.925 0.158 0.075 
27 9 0.225 0.925 0.150 0.075 
27 8 0.225 0.933 0.158 0.067 
27 7 0.225 0.942 0.167 0.058 
27 6 0.225 0.950 0.175 0.050 
>64.04
27 5 0.225 0.958 0.183 0.042 
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>64.09 
>64.32 
>64.68 
>64.96 
>65.60 
>65.91 
>66.28 
>67.17 
>67.59 
>68.66 
>68.95 
>70.41 
>70.74 
>71.56 
>72.23 
>72.35 
>73.38 
>73.73 
>74.48 
>74.79 
>75.75 
>76.05 
>76.47 
>76.54 
>77.49 
>78.30 
>78.82 
>78.83 
>79.02 
>79.79 
>79.92 
>80.30 
>80.60 
>81.96 
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Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
26 5 0.217 0.958 0.175 0.042 
26 4 0.217 0.967 0.183 0.033 
25 4 0.208 0.967 0.175 0.033 
25 3 0.208 0.975 0.183 0.025 
24 3 0.200 0.975 0.175 0.025 
23 3 0.192 0.975 0.167 0.025 
22 3 0.183 0.975 0.158 0.025 
22 2 0.183 0.983 0.167 0.017 
21 2 0.175 0.983 0.158 0.017 
20 2 0.167 0.983 0.150 0.017 
20 1 0.167 0.992 0.158 0.008 
19 1 0.158 0.992 0.150 0.008 
18 1 0.150 0.992 0.142 0.008 
18 0 0.150 1.000 0.150 0.000 
17 0 0.142 1.000 0.142 0.000 
16 0 0.133 1.000 0.133 0.000 
15 0 0.125 1.000 0.125 0.000 
14 0 0.117 1.000 0.117 0.000 
13 0 0.108 1.000 0.108 0.000 
12 0 0.100 1.000 0.100 0.000 
11 0 0.092 1.000 0.092 0.000 
10 0 0.083 1.000 0.083 0.000 
9 0 0.075 1.000 0.075 0.000 
8 0 0.067 1.000 0.067 0.000 
7 0 0.058 1.000 0.058 0.000 
6 0 0.050 1.000 0.050 0.000 
5 0 0.042 1.000 0.042 0.000 
4 0 0.033 1.000 0.033 0.000 
3 0 0.025 1.000 0.025 0.000 
2 0 0.017 1.000 0.017 0.000 
 1 0 0.008 1.000 0.008 0.000 
a Gray shading denotes the cutoff value, sensitivity and specificity at the highest 
Youden's score. 
Abbreviations: EA-D, early antigen-diffuse; IgG, immunoglobulin G; ROC, receiver 
operating characteristics; PP, percentage positivity; NPC, nasopharyngeal carcinoma. 
 
Appendix A, continued. 
>140.94 1 0 0.000 1.000 0.000 0.000 
>82.82 
>83.04 
>83.49 
>83.92 
>84.86 
>88.17 
>88.24 
>89.07 
>89.49 
>91.60 
>92.91 
>93.30 
>94.29 
>94.41 
>97.80 
>98.92 
>99.05 
>101.63 
>105.34 
>106.76 
>106.97 
>107.63 
>108.82 
>110.15 
>111.50 
>112.35 
>112.67 
>131.23 
>132.00 
>134.35
>82.63
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Appendix B. Counting of study subjects according to ZEBRA/IgG positivity (cutoff 
values), Youden's index and coordinates of the ROC curve.a 
Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
≥9.51 120 120 1.000 0.000 0.000 1.000 
120 119 1.000 0.008 0.008 0.992 
120 118 1.000 0.017 0.017 0.983 
120 117 1.000 0.025 0.025 0.975 
120 116 1.000 0.033 0.033 0.967 
120 115 1.000 0.042 0.042 0.958 
120 114 1.000 0.050 0.050 0.950 
120 113 1.000 0.058 0.058 0.942 
120 112 1.000 0.067 0.067 0.933 
120 111 1.000 0.075 0.075 0.925 
120 110 1.000 0.083 0.083 0.917 
120 109 1.000 0.092 0.092 0.908 
120 108 1.000 0.100 0.100 0.900 
119 108 0.992 0.100 0.092 0.900 
119 107 0.992 0.108 0.100 0.892 
119 106 0.992 0.117 0.108 0.883 
119 105 0.992 0.125 0.117 0.875 
119 104 0.992 0.133 0.125 0.867 
119 103 0.992 0.142 0.133 0.858 
119 102 0.992 0.150 0.142 0.850 
119 101 0.992 0.158 0.150 0.842 
118 101 0.983 0.158 0.142 0.842 
118 100 0.983 0.167 0.150 0.833 
117 100 0.975 0.167 0.142 0.833 
117 99 0.975 0.175 0.150 0.825 
117 98 0.975 0.183 0.158 0.817 
117 97 0.975 0.192 0.167 0.808 
116 97 0.967 0.192 0.158 0.808 
116 96 0.967 0.200 0.167 0.800 
116 95 0.967 0.208 0.175 0.792 
115 95 0.958 0.208 0.167 0.792 
115 94 0.958 0.217 0.175 0.783 
115 93 0.958 0.225 0.183 0.775 
>9.51
 115 92 0.958 0.233 0.192 0.767 
>11.84 
>14.09 
>19.12 
>21.73 
>21.83 
>21.86 
>21.92 
>22.11 
>22.63 
>23.20 
>24.63 
>24.90 
>25.00 
>25.65 
>26.19 
>26.32 
>26.48 
>26.70 
>26.90 
>27.01 
>28.24 
>28.38 
>29.16 
>29.17 
>29.50 
>30.37 
>30.49 
>31.97 
>32.51 
>33.39 
>33.93 
>34.27
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Appendix B, continued. 
Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
115 91 0.958 0.242 0.200 0.758 
115 90 0.958 0.250 0.208 0.750 
115 89 0.958 0.258 0.217 0.742 
115 88 0.958 0.267 0.225 0.733 
115 87 0.958 0.275 0.233 0.725 
115 86 0.958 0.283 0.242 0.717 
115 85 0.958 0.292 0.250 0.708 
114 85 0.950 0.292 0.242 0.708 
113 85 0.942 0.292 0.233 0.708 
113 84 0.942 0.300 0.242 0.700 
113 83 0.942 0.308 0.250 0.692 
113 82 0.942 0.317 0.258 0.683 
112 82 0.933 0.317 0.250 0.683 
112 81 0.933 0.325 0.258 0.675 
112 80 0.933 0.333 0.267 0.667 
111 80 0.925 0.333 0.258 0.667 
111 79 0.925 0.342 0.267 0.658 
110 79 0.917 0.342 0.258 0.658 
110 78 0.917 0.350 0.267 0.650 
109 78 0.908 0.350 0.258 0.650 
108 78 0.900 0.350 0.250 0.650 
108 77 0.900 0.358 0.258 0.642 
108 76 0.900 0.367 0.267 0.633 
107 76 0.892 0.367 0.258 0.633 
107 75 0.892 0.375 0.267 0.625 
107 74 0.892 0.383 0.275 0.617 
107 73 0.892 0.392 0.283 0.608 
107 72 0.892 0.400 0.292 0.600 
107 71 0.892 0.408 0.300 0.592 
107 70 0.892 0.417 0.308 0.583 
107 69 0.892 0.425 0.317 0.575 
107 68 0.892 0.433 0.325 0.567 
106 68 0.883 0.433 0.317 0.567 
105 68 0.875 0.433 0.308 0.567 
>34.36
 105 67 0.875 0.442 0.317 0.558 
>34.37 
>34.75 
>35.32 
>35.39 
>35.56 
>35.76 
>36.15 
>36.41 
>36.49 
>36.79 
>36.85 
>37.15 
>37.81 
>38.78 
>39.14 
>39.72 
>39.94 
>40.02 
>40.32 
>41.45 
>41.48 
>42.04 
>42.09 
>42.11 
>42.12 
>42.29 
>42.38 
>42.44 
>42.49 
>42.88 
>43.05 
>43.07 
>43.52 
>43.54
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Appendix B, continued. 
Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
 105 66 0.875 0.450 0.325 0.550 
 104 66 0.867 0.450 0.317 0.550 
 103 66 0.858 0.450 0.308 0.550 
 103 65 0.858 0.458 0.317 0.542 
 103 64 0.858 0.467 0.325 0.533 
 103 63 0.858 0.475 0.333 0.525 
 103 62 0.858 0.483 0.342 0.517 
 103 61 0.858 0.492 0.350 0.508 
 103 60 0.858 0.500 0.358 0.500 
 103 59 0.858 0.508 0.367 0.492 
 103 58 0.858 0.517 0.375 0.483 
 103 57 0.858 0.525 0.383 0.475 
 103 56 0.858 0.533 0.392 0.467 
 103 55 0.858 0.542 0.400 0.458 
 103 54 0.858 0.550 0.408 0.450 
 103 53 0.858 0.558 0.417 0.442 
 102 53 0.850 0.558 0.408 0.442 
 102 52 0.850 0.567 0.417 0.433 
 101 52 0.842 0.567 0.408 0.433 
 100 52 0.833 0.567 0.400 0.433 
 100 51 0.833 0.575 0.408 0.425 
 100 50 0.833 0.583 0.417 0.417 
 100 49 0.833 0.592 0.425 0.408 
 99 49 0.825 0.592 0.417 0.408 
 99 48 0.825 0.600 0.425 0.400 
 98 48 0.817 0.600 0.417 0.400 
 98 47 0.817 0.608 0.425 0.392 
 98 46 0.817 0.617 0.433 0.383 
 97 46 0.808 0.617 0.425 0.383 
 96 46 0.800 0.617 0.417 0.383 
 95 46 0.792 0.617 0.408 0.383 
 95 45 0.792 0.625 0.417 0.375 
 95 44 0.792 0.633 0.425 0.367 
 94 44 0.783 0.633 0.417 0.367 
>43.70
 94 43 0.783 0.642 0.425 0.358 
>44.19
>44.35
>44.40
>44.71
>44.83
>45.50
>45.57
>45.72
>45.80
>46.25
>46.62
>46.87
>47.02
>47.04
>48.48
>49.39
>50.69
>51.18
>51.24
>51.61
>51.90
>52.21
>53.75
>53.82
>54.09
>54.44
>55.08
>55.09
>55.48
>55.70
>55.85
>56.18
>56.69
>56.89
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Appendix B, continued. 
Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
 93 43 0.775 0.642 0.417 0.358 
 92 43 0.767 0.642 0.408 0.358 
 91 43 0.758 0.642 0.400 0.358 
 91 42 0.758 0.650 0.408 0.350 
 90 42 0.750 0.650 0.400 0.350 
 89 42 0.742 0.650 0.392 0.350 
 89 41 0.742 0.658 0.400 0.342 
 88 41 0.733 0.658 0.392 0.342 
 87 41 0.725 0.658 0.383 0.342 
 87 40 0.725 0.667 0.392 0.333 
 86 40 0.717 0.667 0.383 0.333 
 86 39 0.717 0.675 0.392 0.325 
 86 38 0.717 0.683 0.400 0.317 
 85 38 0.708 0.683 0.392 0.317 
 85 37 0.708 0.692 0.400 0.308 
 85 36 0.708 0.700 0.408 0.300 
 85 35 0.708 0.708 0.417 0.292 
 84 35 0.700 0.708 0.408 0.292 
 83 35 0.692 0.708 0.400 0.292 
 83 34 0.692 0.717 0.408 0.283 
 83 33 0.692 0.725 0.417 0.275 
 82 33 0.683 0.725 0.408 0.275 
 82 32 0.683 0.733 0.417 0.267 
 81 32 0.675 0.733 0.408 0.267 
 81 31 0.675 0.742 0.417 0.258 
 80 31 0.667 0.742 0.408 0.258 
 80 30 0.667 0.750 0.417 0.250 
 79 30 0.658 0.750 0.408 0.250 
 78 30 0.650 0.750 0.400 0.250 
 78 29 0.650 0.758 0.408 0.242 
 78 28 0.650 0.767 0.417 0.233 
 77 28 0.642 0.767 0.408 0.233 
 76 28 0.633 0.767 0.400 0.233 
 75 28 0.625 0.767 0.392 0.233 
>56.90
 75 27 0.625 0.775 0.400 0.225 
>57.26
>58.12
>58.30
>58.41
>58.68
>58.98
>59.11
>59.88
>60.13
>60.51
>60.63
>60.75
>60.81
>61.67
>61.88
>62.14
>63.11
>63.48
>64.37
>64.86
>65.97
>66.37
>67.17
>67.38
>67.94
>68.39
>69.59
>69.92
>70.77
>71.06
>71.14
>71.54
>71.69
>71.74
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Appendix B, continued. 
Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
75 26 0.625 0.783 0.408 0.217 
74 26 0.617 0.783 0.400 0.217 
73 26 0.608 0.783 0.392 0.217 
72 26 0.600 0.783 0.383 0.217 
72 25 0.600 0.792 0.392 0.208 
71 25 0.592 0.792 0.383 0.208 
70 25 0.583 0.792 0.375 0.208 
70 24 0.583 0.800 0.383 0.200 
69 24 0.575 0.800 0.375 0.200 
69 23 0.575 0.808 0.383 0.192 
68 23 0.567 0.808 0.375 0.192 
68 22 0.567 0.817 0.383 0.183 
67 22 0.558 0.817 0.375 0.183 
67 21 0.558 0.825 0.383 0.175 
67 20 0.558 0.833 0.392 0.167 
66 20 0.550 0.833 0.383 0.167 
65 20 0.542 0.833 0.375 0.167 
65 19 0.542 0.842 0.383 0.158 
64 19 0.533 0.842 0.375 0.158 
63 19 0.525 0.842 0.367 0.158 
63 18 0.525 0.850 0.375 0.150 
62 18 0.517 0.850 0.367 0.150 
62 17 0.517 0.858 0.375 0.142 
61 17 0.508 0.858 0.367 0.142 
61 16 0.508 0.867 0.375 0.133 
60 16 0.500 0.867 0.367 0.133 
59 16 0.492 0.867 0.358 0.133 
59 15 0.492 0.875 0.367 0.125 
58 15 0.483 0.875 0.358 0.125 
58 14 0.483 0.883 0.367 0.117 
57 14 0.475 0.883 0.358 0.117 
56 14 0.467 0.883 0.350 0.117 
56 13 0.467 0.892 0.358 0.108 
55 13 0.458 0.892 0.350 0.108 
>72.39
 54 13 0.450 0.892 0.342 0.108 
>72.82 
>72.96 
>73.19 
>73.55 
>73.56 
>73.71 
>73.95 
>74.40 
>75.72 
>76.22 
>76.23 
>76.47 
>77.24 
>77.25 
>77.32 
>77.61 
>78.19 
>78.30 
>78.39 
>78.52 
>78.60 
>78.77 
>79.02 
>79.10 
>79.64 
>79.83 
>79.85 
>80.66 
>81.72 
>82.52 
>83.02 
>83.34 
>83.61 
>84.30
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Appendix B, continued. 
Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
54 12 0.450 0.900 0.350 0.100 
53 12 0.442 0.900 0.342 0.100 
53 11 0.442 0.908 0.350 0.092 
52 11 0.433 0.908 0.342 0.092 
51 11 0.425 0.908 0.333 0.092 
51 10 0.425 0.917 0.342 0.083 
51 9 0.425 0.925 0.350 0.075 
51 8 0.425 0.933 0.358 0.067 
50 8 0.417 0.933 0.350 0.067 
49 8 0.408 0.933 0.342 0.067 
49 7 0.408 0.942 0.350 0.058 
48 7 0.400 0.942 0.342 0.058 
47 7 0.392 0.942 0.333 0.058 
46 7 0.383 0.942 0.325 0.058 
46 6 0.383 0.950 0.333 0.050 
45 6 0.375 0.950 0.325 0.050 
45 5 0.375 0.958 0.333 0.042 
44 5 0.367 0.958 0.325 0.042 
44 4 0.367 0.967 0.333 0.033 
43 4 0.358 0.967 0.325 0.033 
42 4 0.350 0.967 0.317 0.033 
42 3 0.350 0.975 0.325 0.025 
41 3 0.342 0.975 0.317 0.025 
40 3 0.333 0.975 0.308 0.025 
39 3 0.325 0.975 0.300 0.025 
38 3 0.317 0.975 0.292 0.025 
37 3 0.308 0.975 0.283 0.025 
37 2 0.308 0.983 0.292 0.017 
36 2 0.300 0.983 0.283 0.017 
35 2 0.292 0.983 0.275 0.017 
34 2 0.283 0.983 0.267 0.017 
 33 2 0.275 0.983 0.258 0.017 
 32 2 0.267 0.983 0.250 0.017 
 31 2 0.258 0.983 0.242 0.017 
>84.70
 30 2 0.250 0.983 0.233 0.017 
>86.16 
>86.60 
>86.84 
>87.03 
>87.13 
>87.33 
>88.52 
>88.59 
>89.10 
>89.36 
>90.05 
>90.26 
>90.80 
>90.86 
>91.60 
>91.69 
>92.28 
>92.66 
>92.71 
>94.38 
>94.58 
>94.77 
>94.86 
>94.92 
>95.02 
>96.02 
>97.38 
>97.66 
>98.45 
>99.09 
>99.23 
>100.65
>100.72
>101.06
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Appendix B, continued. 
Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
 29 2 0.242 0.983 0.225 0.017 
 28 2 0.233 0.983 0.217 0.017 
 27 2 0.225 0.983 0.208 0.017 
 27 1 0.225 0.992 0.217 0.008 
 26 1 0.217 0.992 0.208 0.008 
 25 1 0.208 0.992 0.200 0.008 
 24 1 0.200 0.992 0.192 0.008 
 23 1 0.192 0.992 0.183 0.008 
 22 1 0.183 0.992 0.175 0.008 
 21 1 0.175 0.992 0.167 0.008 
 20 1 0.167 0.992 0.158 0.008 
 19 1 0.158 0.992 0.150 0.008 
 18 1 0.150 0.992 0.142 0.008 
 17 1 0.142 0.992 0.133 0.008 
 16 1 0.133 0.992 0.125 0.008 
 15 1 0.125 0.992 0.117 0.008 
 14 1 0.117 0.992 0.108 0.008 
 14 0 0.117 1.000 0.117 0.000 
 13 0 0.108 1.000 0.108 0.000 
 12 0 0.100 1.000 0.100 0.000 
 11 0 0.092 1.000 0.092 0.000 
 10 0 0.083 1.000 0.083 0.000 
 9 0 0.075 1.000 0.075 0.000 
 8 0 0.067 1.000 0.067 0.000 
 7 0 0.058 1.000 0.058 0.000 
 6 0 0.050 1.000 0.050 0.000 
 5 0 0.042 1.000 0.042 0.000 
 4 0 0.033 1.000 0.033 0.000 
 3 0 0.025 1.000 0.025 0.000 
 2 0 0.017 1.000 0.017 0.000 
 1 0 0.008 1.000 0.008 0.000 
a Gray shading denotes the cutoff value, sensitivity and specificity at the highest 
Youden's score. 
Abbreviations: ZEBRA, Z-encoded broadly reactive activator; IgG, immunoglobulin G; 
ROC, receiver operating characteristics; PP, percentage positivity; NPC, 
nasopharyngeal carcinoma.  
>123.16 0 0 0.000 1.000 0.000 0.000 
>103.11
>103.23
>103.62
>103.70
>104.39
>104.63
>104.72
>104.93
>105.59
>105.94
>106.57
>107.13
>107.21
>107.77
>108.04
>108.06
>109.01
>109.58
>110.20
>110.53
>110.60
>111.80
>111.83
>112.15
>112.78
>113.29
>116.26
>116.27
>116.55
>119.61
>101.37
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Appendix C. Counting of study subjects according to VCA p18/IgG positivity (cutoff 
values), Youden's index and coordinates of the ROC curve.a 
Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
≥6.41 120 120 1.000 0.000 0.000 1.000 
120 119 1.000 0.008 0.008 0.992 
120 118 1.000 0.017 0.017 0.983 
120 117 1.000 0.025 0.025 0.975 
120 116 1.000 0.033 0.033 0.967 
120 115 1.000 0.042 0.042 0.958 
120 114 1.000 0.050 0.050 0.950 
120 113 1.000 0.058 0.058 0.942 
120 112 1.000 0.067 0.067 0.933 
120 111 1.000 0.075 0.075 0.925 
120 110 1.000 0.083 0.083 0.917 
120 109 1.000 0.092 0.092 0.908 
120 108 1.000 0.100 0.100 0.900 
119 108 0.992 0.100 0.092 0.900 
119 107 0.992 0.108 0.100 0.892 
119 106 0.992 0.117 0.108 0.883 
118 106 0.983 0.117 0.100 0.883 
117 106 0.975 0.117 0.092 0.883 
117 105 0.975 0.125 0.100 0.875 
117 104 0.975 0.133 0.108 0.867 
117 103 0.975 0.142 0.117 0.858 
117 102 0.975 0.150 0.125 0.850 
117 101 0.975 0.158 0.133 0.842 
117 100 0.975 0.167 0.142 0.833 
117 99 0.975 0.175 0.150 0.825 
117 98 0.975 0.183 0.158 0.817 
117 97 0.975 0.192 0.167 0.808 
117 96 0.975 0.200 0.175 0.800 
117 95 0.975 0.208 0.183 0.792 
117 94 0.975 0.217 0.192 0.783 
117 93 0.975 0.225 0.200 0.775 
117 92 0.975 0.233 0.208 0.767 
117 91 0.975 0.242 0.217 0.758 
>6.41
 117 90 0.975 0.250 0.225 0.750 
>7.87 
>8.03 
>8.13 
>8.84 
>9.05 
>9.37 
>9.83 
>11.36 
>11.80 
>12.38 
>12.46 
>12.62 
>12.76 
>13.18 
>13.57 
>13.67 
>13.89 
>13.95 
>14.67 
>15.42 
>15.55 
>15.99 
>16.21 
>16.26 
>16.30 
>16.70 
>16.93 
>17.48 
>17.76 
>17.81 
>18.04 
>18.05
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Appendix C, continued. 
Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
 117 89 0.975 0.258 0.233 0.742 
 117 88 0.975 0.267 0.242 0.733 
 116 88 0.967 0.267 0.233 0.733 
 115 88 0.958 0.267 0.225 0.733 
 115 87 0.958 0.275 0.233 0.725 
 115 86 0.958 0.283 0.242 0.717 
 115 85 0.958 0.292 0.250 0.708 
 115 84 0.958 0.300 0.258 0.700 
 115 83 0.958 0.308 0.267 0.692 
 115 82 0.958 0.317 0.275 0.683 
 115 81 0.958 0.325 0.283 0.675 
 115 80 0.958 0.333 0.292 0.667 
 115 79 0.958 0.342 0.300 0.658 
 115 78 0.958 0.350 0.308 0.650 
 114 78 0.950 0.350 0.300 0.650 
 113 78 0.942 0.350 0.292 0.650 
 112 77 0.933 0.358 0.292 0.642 
 112 76 0.933 0.367 0.300 0.633 
 111 76 0.925 0.367 0.292 0.633 
 110 76 0.917 0.367 0.283 0.633 
 109 76 0.908 0.367 0.275 0.633 
 109 75 0.908 0.375 0.283 0.625 
 108 75 0.900 0.375 0.275 0.625 
 107 75 0.892 0.375 0.267 0.625 
 106 75 0.883 0.375 0.258 0.625 
 105 75 0.875 0.375 0.250 0.625 
 105 74 0.875 0.383 0.258 0.617 
 104 74 0.867 0.383 0.250 0.617 
 104 73 0.867 0.392 0.258 0.608 
 103 73 0.858 0.392 0.250 0.608 
 103 72 0.858 0.400 0.258 0.600 
 102 72 0.850 0.400 0.250 0.600 
 102 71 0.850 0.408 0.258 0.592 
 101 71 0.842 0.408 0.250 0.592 
>18.41
 101 70 0.842 0.417 0.258 0.583 
>19.22
>19.63
>19.95
>20.06
>20.18
>20.26
>20.95
>21.03
>21.15
>21.16
>21.34
>21.43
>21.53
>21.61
>22.17
>22.29
>23.01
>23.67
>24.32
>25.45
>25.85
>26.88
>27.06
>27.21
>27.40
>27.43
>27.65
>28.31
>28.36
>28.63
>29.65
>30.07
>30.09
>30.32
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Appendix C, continued. 
Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
100 70 0.833 0.417 0.250 0.583 
100 69 0.833 0.425 0.258 0.575 
99 69 0.825 0.425 0.250 0.575 
98 69 0.817 0.425 0.242 0.575 
97 69 0.808 0.425 0.233 0.575 
96 69 0.800 0.425 0.225 0.575 
96 68 0.800 0.433 0.233 0.567 
95 68 0.792 0.433 0.225 0.567 
95 67 0.792 0.442 0.233 0.558 
95 66 0.792 0.450 0.242 0.550 
94 66 0.783 0.450 0.233 0.550 
94 65 0.783 0.458 0.242 0.542 
94 64 0.783 0.467 0.250 0.533 
93 64 0.775 0.467 0.242 0.533 
93 63 0.775 0.475 0.250 0.525 
92 63 0.767 0.475 0.242 0.525 
92 62 0.767 0.483 0.250 0.517 
92 61 0.767 0.492 0.258 0.508 
92 60 0.767 0.500 0.267 0.500 
92 59 0.767 0.508 0.275 0.492 
92 58 0.767 0.517 0.283 0.483 
92 57 0.767 0.525 0.292 0.475 
92 56 0.767 0.533 0.300 0.467 
91 56 0.758 0.533 0.292 0.467 
91 55 0.758 0.542 0.300 0.458 
90 55 0.750 0.542 0.292 0.458 
89 55 0.742 0.542 0.283 0.458 
88 55 0.733 0.542 0.275 0.458 
87 55 0.725 0.542 0.267 0.458 
86 55 0.717 0.542 0.258 0.458 
85 55 0.708 0.542 0.250 0.458 
84 55 0.700 0.542 0.242 0.458 
83 55 0.692 0.542 0.233 0.458 
82 55 0.683 0.542 0.225 0.458 
>30.43
 82 54 0.683 0.550 0.233 0.450 
>30.44 
>30.79 
>31.29 
>31.29 
>31.77 
>32.19 
>32.23 
>32.34 
>32.41 
>32.49 
>32.70 
>33.12 
>33.33 
>33.37 
>33.43 
>33.54 
>33.97 
>34.08 
>34.37 
>34.37 
>34.56 
>34.67 
>34.71 
>34.76 
>34.90 
>35.01 
>35.84 
>35.98 
>36.45 
>36.46 
>36.82 
>36.98 
>37.08 
>37.12
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Appendix C, continued. 
Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
82 53 0.683 0.558 0.242 0.442 
81 53 0.675 0.558 0.233 0.442 
81 52 0.675 0.567 0.242 0.433 
80 52 0.667 0.567 0.233 0.433 
79 52 0.658 0.567 0.225 0.433 
79 51 0.658 0.575 0.233 0.425 
79 50 0.658 0.583 0.242 0.417 
78 50 0.650 0.583 0.233 0.417 
78 49 0.650 0.592 0.242 0.408 
77 49 0.642 0.592 0.233 0.408 
77 48 0.642 0.600 0.242 0.400 
77 47 0.642 0.608 0.250 0.392 
76 47 0.633 0.608 0.242 0.392 
76 46 0.633 0.617 0.250 0.383 
75 46 0.625 0.617 0.242 0.383 
74 46 0.617 0.617 0.233 0.383 
74 45 0.617 0.625 0.242 0.375 
74 44 0.617 0.633 0.250 0.367 
74 43 0.617 0.642 0.258 0.358 
73 43 0.608 0.642 0.250 0.358 
73 42 0.608 0.650 0.258 0.350 
72 42 0.600 0.650 0.250 0.350 
72 41 0.600 0.658 0.258 0.342 
71 41 0.592 0.658 0.250 0.342 
70 41 0.583 0.658 0.242 0.342 
70 40 0.583 0.667 0.250 0.333 
70 39 0.583 0.675 0.258 0.325 
69 39 0.575 0.675 0.250 0.325 
69 38 0.575 0.683 0.258 0.317 
68 38 0.567 0.683 0.250 0.317 
68 37 0.567 0.692 0.258 0.308 
67 37 0.558 0.692 0.250 0.308 
67 36 0.558 0.700 0.258 0.300 
66 36 0.550 0.700 0.250 0.300 
>37.12
 65 36 0.542 0.700 0.242 0.300 
>37.32 
>37.38 
>37.78 
>38.35 
>39.18 
>39.54 
>39.55 
>39.67 
>40.11 
>40.30 
>40.79 
>40.92 
>40.99 
>41.15 
>41.63 
>41.70 
>41.71 
>42.38 
>43.04 
>43.48 
>43.72 
>44.31 
>45.08 
>45.38 
>45.78 
>45.86 
>45.94 
>46.91 
>47.37 
>47.53 
>48.24 
>48.37 
>49.43 
>49.84
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Appendix C, continued. 
Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
 65 35 0.542 0.708 0.250 0.292 
 64 35 0.533 0.708 0.242 0.292 
 63 35 0.525 0.708 0.233 0.292 
 63 34 0.525 0.717 0.242 0.283 
 63 33 0.525 0.725 0.250 0.275 
 62 33 0.517 0.725 0.242 0.275 
 62 32 0.517 0.733 0.250 0.267 
 62 31 0.517 0.742 0.258 0.258 
 61 31 0.508 0.742 0.250 0.258 
 61 30 0.508 0.750 0.258 0.250 
 61 29 0.508 0.758 0.267 0.242 
 61 28 0.508 0.767 0.275 0.233 
 60 28 0.500 0.767 0.267 0.233 
 59 28 0.492 0.767 0.258 0.233 
 58 28 0.483 0.767 0.250 0.233 
 58 27 0.483 0.775 0.258 0.225 
 58 26 0.483 0.783 0.267 0.217 
 57 26 0.475 0.783 0.258 0.217 
 56 26 0.467 0.783 0.250 0.217 
 55 26 0.458 0.783 0.242 0.217 
 54 26 0.450 0.783 0.233 0.217 
 53 26 0.442 0.783 0.225 0.217 
 52 26 0.433 0.783 0.217 0.217 
 51 26 0.425 0.783 0.208 0.217 
 50 26 0.417 0.783 0.200 0.217 
 49 26 0.408 0.783 0.192 0.217 
 49 25 0.408 0.792 0.200 0.208 
 49 24 0.408 0.800 0.208 0.200 
 49 23 0.408 0.808 0.217 0.192 
 48 23 0.400 0.808 0.208 0.192 
 47 23 0.392 0.808 0.200 0.192 
 46 23 0.383 0.808 0.192 0.192 
 46 22 0.383 0.817 0.200 0.183 
 46 21 0.383 0.825 0.208 0.175 
>50.83
 45 21 0.375 0.825 0.200 0.175 
>51.18
>51.33
>52.09
>52.29
>52.47
>52.57
>52.73
>52.79
>53.19
>54.22
>54.49
>55.03
>55.12
>56.30
>56.39
>57.85
>57.92
>58.02
>58.37
>59.02
>59.41
>59.44
>60.04
>60.34
>60.81
>61.16
>61.44
>61.58
>61.91
>63.07
>63.11
>63.28
>63.51
>63.77
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Appendix C, continued. 
Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
 44 21 0.367 0.825 0.192 0.175 
 44 20 0.367 0.833 0.200 0.167 
 43 20 0.358 0.833 0.192 0.167 
 42 20 0.350 0.833 0.183 0.167 
 41 20 0.342 0.833 0.175 0.167 
 40 20 0.333 0.833 0.167 0.167 
 40 19 0.333 0.842 0.175 0.158 
 40 18 0.333 0.850 0.183 0.150 
 40 17 0.333 0.858 0.192 0.142 
 40 16 0.333 0.867 0.200 0.133 
 39 16 0.325 0.867 0.192 0.133 
 39 15 0.325 0.875 0.200 0.125 
 38 15 0.317 0.875 0.192 0.125 
 37 15 0.308 0.875 0.183 0.125 
 36 15 0.300 0.875 0.175 0.125 
 36 14 0.300 0.883 0.183 0.117 
 35 14 0.292 0.883 0.175 0.117 
 34 14 0.283 0.883 0.167 0.117 
 34 13 0.283 0.892 0.175 0.108 
 33 13 0.275 0.892 0.167 0.108 
 33 12 0.275 0.900 0.175 0.100 
 32 12 0.267 0.900 0.167 0.100 
 32 11 0.267 0.908 0.175 0.092 
 31 11 0.258 0.908 0.167 0.092 
 30 11 0.250 0.908 0.158 0.092 
 29 11 0.242 0.908 0.150 0.092 
 29 10 0.242 0.917 0.158 0.083 
 29 9 0.242 0.925 0.167 0.075 
 29 8 0.242 0.933 0.175 0.067 
 29 7 0.242 0.942 0.183 0.058 
 29 6 0.242 0.950 0.192 0.050 
 28 6 0.233 0.950 0.183 0.050 
 27 6 0.225 0.950 0.175 0.050 
 26 6 0.217 0.950 0.167 0.050 
>63.99
 25 6 0.208 0.950 0.158 0.050 
>64.86
>65.41
>65.49
>66.07
>66.61
>67.23
>67.47
>67.68
>68.70
>69.03
>69.82
>69.86
>70.10
>70.91
>70.98
>71.76
>73.50
>73.58
>73.62
>74.95
>75.05
>75.71
>75.71
>75.94
>76.51
>76.70
>76.83
>77.23
>78.28
>78.88
>78.98
>79.20
>80.40
>80.48
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Appendix C, continued. 
Cutoff value 
(PP) 
NPC 
(n) 
Normal 
(n) Sensitivity Specificity Youden's index 1 − Specificity 
 24 6 0.200 0.950 0.150 0.050 
 23 6 0.192 0.950 0.142 0.050 
 22 6 0.183 0.950 0.133 0.050 
 22 5 0.183 0.958 0.142 0.042 
 21 5 0.175 0.958 0.133 0.042 
 21 4 0.175 0.967 0.142 0.033 
 20 4 0.167 0.967 0.133 0.033 
 20 3 0.167 0.975 0.142 0.025 
 19 3 0.158 0.975 0.133 0.025 
 18 3 0.150 0.975 0.125 0.025 
 17 3 0.142 0.975 0.117 0.025 
 16 3 0.133 0.975 0.108 0.025 
 16 2 0.133 0.983 0.117 0.017 
 15 2 0.125 0.983 0.108 0.017 
 14 2 0.117 0.983 0.100 0.017 
 13 2 0.108 0.983 0.092 0.017 
 12 2 0.100 0.983 0.083 0.017 
 11 2 0.092 0.983 0.075 0.017 
 11 1 0.092 0.992 0.083 0.008 
 11 0 0.092 1.000 0.092 0.000 
 10 0 0.083 1.000 0.083 0.000 
 9 0 0.075 1.000 0.075 0.000 
 8 0 0.067 1.000 0.067 0.000 
 7 0 0.058 1.000 0.058 0.000 
 6 0 0.050 1.000 0.050 0.000 
 5 0 0.042 1.000 0.042 0.000 
 4 0 0.033 1.000 0.033 0.000 
 3 0 0.025 1.000 0.025 0.000 
 2 0 0.017 1.000 0.017 0.000 
 1 0 0.008 1.000 0.008 0.000 
a Gray shading denotes the cutoff value, sensitivity and specificity at the highest 
Youden's score. 
Abbreviations: VCA, viral capsid antigen; IgG, immunoglobulin G; ROC, receiver 
operating characteristics; PP, percentage positivity; NPC, nasopharyngeal carcinoma. 
  
>82.71
>83.55
>83.94
>84.27
>84.83
>84.98
>86.18
>86.51
>87.25
>87.38
>87.68
>88.14
>91.35
>92.03
>93.15
>94.16
>94.72
>96.24
>98.00
>99.42
>100.66
>100.69
>101.00
>101.03
>102.71
>103.43
>105.23
>105.29
>108.07
>109.30
>120.47 0 0 0.000 1.000 0.000 0.000 
Appendix D. Protein multiple sequence alignments (EA-D, ZEBRA and VCA p18) for EBV strains (B95-8, AG876 and GD1). 
EBV protein Multiple sequence alignmenta UniProt entry EBV strain 
EA-D 1    METTQTLRFKTKALAVLSKCYDHAQTHLKGGVLQVNLLSVNYGGPRLAAVANAGTAGLIS   60 1    METTQTLRFKTKALAVLSKCYDHAQTHLKGGVLQVNLLSVNYGGPRLAAVANAGTAGLIS   60 
1    METTQTLRFKTKALAVLSKCYDHAQTHLKGGVLQVNLLSVNYGGPRLAAVANAGTAGLIS   60 
     ************************************************************ 
P03191
P0C6Z0
Q3KSU3
B95-5
AG876
GD1
61   FEVSPDAVAEWQNHQSPEEAPAAVSFRNLAYGRTCVLGKELFGSAVEQASLQFYKRPQGG  120 
61   FEVSPDAVAEWQNHQSPEEAPAAVSFRNLAYGRTCVLGKELFGSAVEQASLQFYKRPQGG  120 
61   FEVSPDAVAEWQNHQSPEEAPAAVSFRNLAYGRTCVLGKELFGSAVEQASLQFYKRPQGG  120 
     ************************************************************ 
P03191
P0C6Z0
Q3KSU3
B95-5
AG876
GD1
121  SRPEFVKLTMEYDDKVSKSHHTCALMPYMPPASDRLRNEQMIGQVLLMPKTASSLQKWAR  180 
121  SRPEFVKLTMEYDDKVSKSHHTCALMPYMPPASDRLRNEQMIGQVLLMPKTASSLQKWAR  180 
121  SRPEFVKLTMEYDDKVSKSHHTCALMPYMPPASDRLRNEQMIGQVLLMPKTASSLQKWAR  180 
     ************************************************************ 
P03191
P0C6Z0
Q3KSU3
B95-5
AG876
GD1
181  QQGSGGVKVTLNPDLYVTTYTSGEACLTLDYKPLSVGPYEAFTGPVAKAQDVGAVEAHVV  240 
181  QQGSGGVKVTLNPDLYVTTYTSGEACLTLDYKPLSVGPYEAFTGPVAKAQDVGAVEAHVV  240 
181  QQGSGGVKVTLNPDLYVTTYTSGEACLTLDYKPLSVGPYEAFTGPVAKAQDSGAVEAHVV  240 
     *************************************************** ******** 
P03191
P0C6Z0
Q3KSU3
B95-5
AG876
GD1
241  CSVAADSLAAALSLCRIPAVSVPILRFYRSGIIAVVAGLLTSAGDLPLDLSVILFNHASE  300 
241  CSVAADSLAAALSLCRIPAVSVPILRFYRSGIIAVVAGLLTSAGDLPLDLSVILFNHASE  300 
241  CSVAADSLAAALSLCRIPAVSVPILRFYRSGIIAVVAGLLTSAGDLPLDLSVILFNHASE  300 
     ************************************************************ 
P03191
P0C6Z0
Q3KSU3
B95-5
AG876
GD1
301  EAAASTASEPEDKSPRVQPLGTGLQQRPRHTVSPSPSPPPPPRTPTWESPARPETPSPAI  360 
301  EAAASTASEPEDKSPRVQPLGTGLQQRPRHTVSPSPSPPPPPRTPTWESPARPETPSPAI  360 
301  EAAASTASEPEDKSPRVQPLGTGLQQRPRHTVSPSPSPPPPPRTPTWESPARPETPSPAI  360 
     ************************************************************ 
P03191
P0C6Z0
Q3KSU3
B95-5
AG876
GD1
361  PSHSSNTALERPLAVQLARKRTSSEARQKQKHPKKVKQAFNPLI  404 
361  PSHSSNTALERPLAVQLARKRTSSEARQKQKHPKKVKQAFNPLI  404 
361  PSHSSNTALERPLAVQLARKRTSSEARQKQKHPKKVKQAFNPLI  404 
     ********************************************
P03191
P0C6Z0
Q3KSU3
B95-5
AG876
GD1
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Appendix D, continued. 
EBV protein Multiple sequence alignmenta UniProt entry EBV strain 
ZEBRA 1    MMDPNSTSEDVKFTPDPYQVPFVQAFDQATRVYQDLGGPSQAPLPCVLWPVLPEPLPQGQ   60 1    MMDPNSTSEDVKFTPDPYQVPFVQAFDQATRVYQDLGGPSQAPLPCVLWPVLPEPLPQGQ   60 
1    MMDPNSTSEDVKFTPDPYQVPFVQAFDQATRVYQDLGGPSQAPLPCVLWPVLPEPLPQGQ   60 
     ************************************************************ 
P03206
Q1HVG1
Q3KSS8
B95-5
AG876
GD1
61   LTAYHVSTAPTGSWFSAPQPAPENAYQAYAAPQLFPVSDITQNQQTNQAGGEAPQPGDNS  120 
61   LTAYHVSAAPTGSWFPAPQPAPENAYQAYAAPQLFPVSDITQNQQTNQAGGEAPQPGDNS  120 
61   LTAYHVSAAPTGSWFPAPQPAPENAYQAYAAPQLFPVSDITQNQLTNQAGGEAPQPGDNS  120 
     *******:******* **************************** *************** 
P03206
Q1HVG1
Q3KSS8
B95-5
AG876
GD1
121  TVQTAAAVVFACPGANQGQQLADIGVPQPAPVAAPARRTRKPQQPESLEECDSELEIKRY  180 
121  TVQPAAAVVFACPGANQGQQLADIGAPQPAPAAAPARRTRKPLQPESLEECDSELDIKRY  180 
121  TVQPAAAVVLACPGANQEQQLADIGAPQPAPAAAPARRTRKPLQPESLEECDSELEIKRY  180 
     *** *****:******* *******.*****.********** ************:**** 
P03206
Q1HVG1
Q3KSS8
B95-5
AG876
GD1
181  KNRVASRKCRAKFKQLLQHYREVAAAKSSENDRLRLLLKQMCPSLDVDSIIPRTPDVLHE  240 
181  KNRVASRKCRAKFKHLLQHYREVASAKSSENDRLRLLLKQMCPSLDVDSIIPRTPDVLHE  240 
181  KNRVASRKCRAKFKHLLQHYREVASAKSSENDRLRLLLKQMCPSLDVDSIIPRTPDVLHE  240 
     **************:*********:*********************************** 
P03206
Q1HVG1
Q3KSS8
B95-5
AG876
GD1
241  DLLNF  245 
241  DLLNF  245 
241  DLLNF  245 
     ***** 
P03206
Q1HVG1
Q3KSS8
B95-5
AG876
GD1
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Appendix D, continued. 
EBV protein Multiple sequence alignmenta UniProt entry EBV strain 
VCA p18 1    MARRLPKPTLQGRLEADFPDSPLLPKFQELNQNNLPNDVFREAQRSYLVFLTSQFCYEEY   601    MARRLPKPTLQGRLEADFPDSPLLPKFQELNQNNLPNDVFREAQRSYLVFLTSQFCYEEY   60 
1    MARRLPKPTLQGRLEADFPDSPLLPKFQELNQNNLPNDVFREAQRSYLVFLTSQFCYEEY   60 
     ************************************************************ 
P14348
Q1HVI0
Q3KSU9
B95-5
AG876
GD1
61   VQRTFGVPRRQRAIDKRQRASVAGAGAHAHLGGSSATPVQQAQAAASAGTGALASSAPST  120 
61   VQRTFGVPRRQRAIDKRQRASVAGAGAHAHLGGSSATPVQQAQAAASAGTGALASSAPST  120
61   VQRTFGVPRRQRAIDKRQRASVAGAGAHAHLGGSSATPVQQAQAAASAGTGALASSAPST  120
     ************************************************************ 
P14348
Q1HVI0
Q3KSU9
B95-5
AG876
GD1
121  AVAQSATPSVSSSISSLRAATSGATAAASAAAAVDTGSGGGGQPHDTAPRGARKKQ  176 
121  AVAQSATPSVSSSISSLRAATSGATAAASAAAAVDTGSGGGGQPQDTAPRGARKKQ  176 
121  AVAQSATPSVSSSISSLRAATSGATAAASAAAAVDTGSGGGGQPQDTAPRGARKKQ  176 
     ********************************************:*********** 
P14348
Q1HVI0
Q3KSU9
B95-5
AG876
GD1
a Clustal Omega (Sievers et al., 2011) at UniProt (http://www.uniprot.org) was used. Gray shading and asterisk (*), fully conserved residue; 
colon (:), highly similar residue; period (.), weakly similar residue. 
Abbreviations: EBV, Epstein-Barr virus; EA-D, early antigen-diffuse; ZEBRA, Z-encoded broadly reactive activator; VCA, viral capsid antigen. 
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